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Abstract 
Autoimmune hepatitis (AllI) is a chronic hepatitis characterised by the presence of 
liver associated autoantibodies, raised serum gamma globulin levels and interface 
hepatitis on liver histology. There is a strong association with particular human 
leukocyte antigen (HLA) haplotypes and several other non-HLA genes have been 
implicated in contributing to disease severity. The cytotoxic T lymphocyte antigen 4 
(CTLA-4) gene is the best studied non-HLA gene in Am and other autoimmune 
diseases. This study investigated those CTLA-4 gene polymorphisms reported in 
other parts of the world, including the -318 crr promoter polymorphism, +49 AlG 
polymorphism in exon 1 and the CT60 GIA polymorphism in the VTR 3' of the gene, 
in South African patients with Am. A cohort of 118 AllI patients from the MRC-
VCT Liver Research Centre clinic at Groote Schuur Hospital, Cape Town was 
studied for this purpose. In addition, a family-based cohort was selected and 
recruited from 12 Am patients who had family members with either Am or any 
other form of autoimmune disease, to investigate whether there may be any novel, 
disease-associated sequence variations in the CTLA4 gene. To investigate a possible 
role for soluble CTLA4 (sCTLA-4) in the disease progression of Am, the 
concentrations of sCTLA-4 during different stages of AllI disease activity were 
measured in patients, using a commercial ELISA kit. 
No new polymorphisms were identified and sCTLA4 concentrations did not correlate 
with AllI disease activity. The known CTLA4 gene polymorphisms, -318 crr, +49 
AlG and CT60 GIA, were not significantly associated with Am in the South African 
population. At first presentation, females were on average 13.47 years older than 
their male counterparts. Black African patients were, at first presentation, on average 
12.78 years younger than their caucasian counterparts, and had more severe disease, 
as assessed by biochemical parameters. Furthermore, there was a highly significant 
difference in the genotypic frequencies at the CT60 locus amongst ethnic groups. 
Black African patients had the highest frequency of the CT60 GIG genotype, while 
the CT60 AI A genotype was completely absent from this group. This was not 
obviously associated with their disease and needs to be further investigated. 
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Chapter 1 
The Immune System and Autoimmunity: Review 
1.1 Immune System 
In order to protect itself against the disease causing effects of pathogens, the human 
body has developed a complex immune system for foreign antigen detection and 
elimination. The immune system is a highly integrated and effective biological 
system that determines the nature of attack on the body and initiates the appropriate 
response. The first line of defence against pathogens is the protective layer of skin 
and mucous membranes which constitute the ectoderm of the body. If a pathogen 
manages to breach these surfaces, the body has a need for more advanced defences 
against such infection. There are two types of immune responses: the innate or 
natural response, and the acquired or adaptive response (Delves and Roitt 2000a). 
1.1.1 Innate (Natural) Immune System 
Innate immune responses are encoded in the host's germ-line genes and are 
characterised by a non-specific response to infection. Such responses are generic and 
characterised by their inability to change and adapt following repeated activation. 
Various cells and molecular components form part of the innate system. These cells 
(detailed below) are genetically programmed to recognise molecular patterns shared 
by a range of foreign antigens. The innate system constitutes the initial host response 
as it acts very rapidly upon contact with invading pathogens (Chaplin 2003; Delves 
and Roitt 2000a). 
Phagocytic cells like monocytes, macrophages and neutrophils recognise antigens, 
such as microorganisms, and engulf them through phagocytosis. Inside these cells, 
the phagocytosed antigens are exposed to toxic molecules (Delves and Roitt 2000a). 
Apart from their phagocytic properties, neutrophils also produce reactive oxygen 
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species that are cytotoxic to bacteria. Monocytes and macrophages, including 
Langerhans cells, Kupffer cells, microglial cells and certain dendritic cells, have the 
added ability to present digested fragments of antigen to T cell receptors (TCR) 
thereby acting as antigen-presenting cells (APC) (Chaplin 2003). This is achieved 
with the help of class I and II major histocompatability complex (MHC) molecules 
expressed on their surfaces. 
Cells such as eosinophils, basophils and mast cells can act by releasing molecules 
such as cationic proteins and superoxides into extracellular fluids, and playa central 
role in the response to allergens and parasitic infections. These cells also release 
proinflammatory cytokines which attract leukocytes to sites of inflammation 
(Abraham and Arock 1998; Delves and Roitt 2000a). 
Natural killer cells target immunoglobulin (Ig) G coated cells through antibody-
dependent cytotoxicity, and are important in defence against viral infections. They 
also have the ability to recognise and destroy nucleated cells that lack MHC class I 
(MHC I) molecules as a result of microbial interference or malignancy (Chaplin 
2003; Delves and Roitt 2000a). 
1.1.2 Acquired (Adaptive) System 
The acquired immune response is thought to have evolved more recently than the 
innate response. Whereas innate responses remain unchanged, acquired responses 
adapt and strengthen with every pathogen encounter. It does so through the 
rearrangement of germline lymphocyte genes (somatic rearrangement) to establish 
exclusive specificity of lymphocytes to antigens (Chaplin 2003; Delves and Roitt 
2000a). 
Lymphocytes originate in the foetal liver and bone marrow haematopoietic stem 
cells. B-Iymphocytes reach full maturity in the bone marrow, while T lymphocytes 
are relocated to the thymus, where they complete their development and undergo 
negative selection (see section 1.1.3; page 5). Both B and T lymphocytes have 
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receptors that recognise and bind to small epitopes on the surfaces of antigens, 
leading to their activation (Delves and Roitt 2000a). As T lymphocyte activation is 
relevant to this dissertation it is further described in section 1.2; page 7. 
Immature B lymphocytes can recognise many different antigens, through receptors 
on their surface. Once these receptors recognise an antigen, the B cell undergoes 
rapid proliferation to form a vast number of lymphocytes that are highly specific for 
that antigen. During this period of proliferation, B cells mutate rapidly and thereby 
strengthen the specificity of their receptors, increasing the strength of binding to the 
specific antigens. This process is commonly referred to as clonal selection. The 
resultant antigen-specific B lymphocytes secrete high numbers of immunoglobulin or 
antibodies that resemble the B lymphocyte receptors in structure and antigen 
specificity (Delves and Roitt 2000a; Delves and Roitt 2000b; Edelman 1973; Chaplin 
2003). 
During the proliferation period a distinct group of T and B cells, called memory 
cells, are formed. These cells remain in the body after the infection has subsided. In 
the case of a subsequent infection by the same agent, these cells ensure a very rapid 
secondary response that is highly specific to the antigen (Delves and Roitt 2000a; 
Chaplin 2(03). 
1.1.3 Immune Tolerance 
The immune system needs a mechanism to distinguish foreign antigens from the 
body's own proteins, the recognition of self. Tolerance is critical in keeping the 
acquired immune system unresponsive to self-antigens. B cell tolerance is induced 
primarily in the bone marrow, while T cell tolerance is induced in one of two places: 
centrally, in the thymus, or peripherally, in the secondary lymphoid tissues (Abbas et 
al2004; Ermann and Fathman 2001; Simmonds and Gough 2005; Delves and Roitt 
2000a). A breakdown in central or peripheral tolerance results in immune responses 
that are directed against self. This may be organ-specific, as in autoimmune hepatitis 
(Alli) or systemic, leading to multi-systemic autoimmunity, as in systemic lupus 
3 
erythematosus (SLE) (Kristiansen et al 2000, Abbas et al 2004; Simmonds and 
Gough 2005). 
Central tolerance occurs mainly in the foetal thymus via two steps (see figure 1.1). 
The first is when immature thymocytes expressing unique T-cell receptors undergo 
positive selection, resulting in a protective signal that prevents them from undergoing 
apoptosis (programmed cell death). This is achieved when cluster CD4 and CD8 
positive thymocytes interact with MHC human leukocyte antigen (HLA) class I and 
II molecules on thymic cortical epithelial cells. In the second step, only surviving 
thymocytes bearing high affinity receptors for self-MHC molecules interact with 
APCs and thus undergo apoptosis. Through this process of negative selection, only 
T cells highly specific for foreign antigens are allowed to mature and be released into 
the immune system (Simmonds and Gough 2005; Mackay 2000). As most tissue-
specific antigens are not present in the thymus or bone marrow, a second mechanism 
is needed to prevent autoimmunity (Shevach 2000). This is achieved through 
peripheral tolerance. 
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normal Balb/c mice were given to these animals. The re-introduction of Treg cells 
restores self tolerance and prevents autoimmune disease (Sakaguchi et al1985, 
Sakaguchi et al1995, Suri-Payer et al1999; Shevach 2000). 
Other interrelated mechanisms of peripheral tolerance include anergy, a process that 
leaves T cells functionally unresponsive to the self antigens due to the absence of a 
co-stimulatory signal or suboptimal antigen receptor signalling, and deletion by 
apoptosis. Apoptosis of lymphocytes could occur through passive or activation-
induced mechanisms. Passive cell death is thought to occur due to the loss of 
expression of antiapoptotic proteins such as B cell lymphoma (Bcl) family members, 
resulting from a lack of co-stimulation and cytokines. Activation-induced cell death 
results from feedback mechanisms triggered by lymphocyte activation resulting in 
the limitation oflymphocyte proliferation and differentiation (Abbas et a12004; Van 
Parijs and Abbas 1998). As this activation is a critical part in peripheral tolerance and 
the prevention of autoimmunity, it is reviewed in detail in the following section. 
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Figure 1.2 Mechanisms of peripheral T cell tolerance [Adapted from Abbas et a12004]. 
In the normal T cell response, TCRs bind antigen on APCs, followed by the 
binding of CD28 co-stimulatory molecules to 87 receptors on the same APCs 
(see section 1.2.1; page 8). Anergy and deletion ofT lymphocytes byapoptosis 
occur in the absence of the CD28-87 signal. Suppression of activation is 
effected through Treg cells. 
1.2 T Cell Activation 
The activation of T cells requires two signals, the primary activation signal and a 
second, co-stimulatory signal. When the immune system encounters a foreign 
antigen, peptides from the antigen are presented by an APC to an uncommitted 
helper T cell (THO) with the help ofMHC class II molecules. This interaction 
constitutes the first activation signal of the TJJ<> cells which then differentiate into 
either THl or Tu2 phenotypes. This is dependent on the effect of cytokines (small 
peptide signalling molecules) in the cellular environment, the nature of the antigen 
and the affinity oftbe binding between the TCR and MHC/peptide complex. THl 
cells produce interleukin 2 (lL-2) and interferon-gamma (IFN-y) which promote cell-
mediated immune responses through activation of macropbages and cytotoxic T 
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lymphocytes. T H2 cells, on the other hand, release IL-4, IL-5 and IL-l 0 which 
promote the production of antibodies by B cells (McFarlane and Heneghan 2004). 
1.2.1 Co-stimulatory Pathway 
CD28, which is a member of the Ig gene superfamily on peripheral T cells, together 
with its ligands CD80 (B7-1) and CD86 (B7-2) on APCs, provide the second, antigen 
independent co-stimulatory signal (see figure 1.3) (Boise et a11995; Chambers 2001; 
Simmonds and Gough 2005). Absence of this second signal results in the inability of 
the cells to respond to future activation signals (anergy) or even apoptosis (Boise et 
al. 1995; Sansom 2000). 
Besides lowering the threshold for antigenic stimulation, CD28 co-stimulation also 
plays a critical role in maintaining T cell growth and proliferation through the 
upregulation of IL-2, significantly influencing T cell differentiation and augmenting 
T cell survival (Rulifson et a11997; Boise et a11995; Bluestone 1997) 
This CD28 T cell co-stimulation is regulated by another member of the Ig gene 
superfamily, namely CTLA4. CTLA4, unlike CD28, is not found on resting T cells 
(Purohit et a12005; Krummel and Allison 1995; Thompson and Allison 1997). 
However, upon T cell activation, CTLA4 is upregulated on the cell surface, where it 
functions as a T cell activation inhibitor by actively competing for the CD28 ligands 
(B7 -1 and B 7 -2) and thereby increasing the threshold of activation for otherwise 
weak TCR engagements (Sansom 2000; Egen and Allison 2002). Therefore, in the 
absence of sufficient CTLA4, self-antigens can potentially initiate autoimmunity 
through uninterrupted and sustained co-stimulation (Abbas et aI2004). Indeed, 
CTLA4-deficient mice present with a severe lymphoproliferative disorder and 
autoimmune disease (Waterhouse et aI1995). Furthermore, CTLA4-Ig (a soluble 
fusion protein of human CTLA4 and the IgG 1 constant region) treatment in mice has 
been shown to effectively block interaction of CD28 with its ligand, thereby 
inhibiting transplant rejection and inducing donor specific tolerance (Lenschow et al 
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CTLA4 interacts with its ligands with a 10- to 50-fold higher affinity and 40- to 100-
fold faster kinetics than CD28. Therefore, the amount ofCTLA4 at the cell surface 
needs to be regulated. The cytoplasmic tail of CTLA4 initiates this regulation by 
facilitating the interaction ofthe CTLA4 protein with the c1athrin pit adaptor 
complex (AP-50), causing it to be rapidly internalised (see figure 1.3) (Egen and 
Allison 2002; Sansom 2000; Kristiansen et al 2000; Van der Merwe et al 1997; 
Chambers 2001). 
The CTLA4 protein has a reported half-life of about 2 h. Because of this relatively 
short turnover rate, the efficient transcription of the CTLA4 gene and translation of 
its mRNA into protein is important for its optimal functioning as a regulatory ligand 
(Egen and Allison 2002). 
CTLA4 is also thought to function by interrupting signal transduction. It may 
achieve this by recruiting and ordering intracellular signalling components to the T 
cell-APC synapse through a so-called YVKM motif in its cytoplasmic tail. This 
model is also partly based on the anticipated organisation of CTLA41B7 complexes 
in the immunological synapse (Ostrov et a12000; Sansom 2000; Chambers 2001). 
The CD28/CTLA4Iigands, B7-1 and B7-2 share about 25% sequence homology and 
are thought to perform different functions. Although B7-2 is more abundant on 
resting APCs and is upregulated faster than B7 -1 upon activation, B7 -1 is thought to 
be a stronger ligand for CD28-mediated activation and has a higher affInity for both 
CD28 and CTLA4 (Sansom 2000). 
Therefore it is thought that CTLA4 controls the rate ofT cell activation even in low 
cell surface numbers, and is therefore considered a good candidate gene for 
autoimmune disease susceptibility studies (Simmonds and Gough 2005). 
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1.3 Autoimmunity 
It is estimated that approximately 1 in 31 people in the USA (3.2%) suffer from at 
least one autoimmune disease, the most prevalent forms of which include Graves' 
disease (1151.51100,000), insulin dependent diabetes mellitus (IDDM) 
(1921100,000), rheumatoid arthritis (RA) (860/100,000), hypothyroidism 
(791.61100,000) and vitiligo (400.21100,000) (Jacobson et al1997; Vyse and Todd 
1996). Women have an estimated 2.7 times greater risk than men for developing an 
autoimmune disease although the reason for this is still unclear. Indeed, the effect of 
hormones and genes on the immune response is being investigated (Jacobson et al 
1997; McFarlane and Henegan 2004; Whitacre 2001). In general it is probably true 
to state that autoimmune diseases result from complex and incompletely understood 
interactions between the environment and an individual's genetic susceptibility. 
Certainly, the complex phenotypes observed for autoimmune diseases, such as AIH, 
cannot be explained by a single genetic defect or environmental factor (Kristiansen et 
aI2000). 
1.3.1 Environmental Factors 
Autoimmune disease is thought to be induced in susceptible individuals through 
environmental triggering factors such as infectious agents, toxins and drugs. Some 
drugs that have been described as possible triggering factors include the statins 
(atorvastatin and simvastatin), imatinib mesylate and IFNP (Czaja 2000). 
Furthermore, it has been suggested that the triggering epitope in some autoimmune 
conditions is a short amino acid sequence shared by many antigens. An immune 
response directed against an epitope of a foreign antigen that is similar or identical to 
a self protein, could hypothetically result in the immune response being misdirected 
against self. This cross-reactivity is referred to as molecular mimicry and could lead 
to autoimmune disease (Ermann and Fathman 2001; Czaja 2005). The molecular 
mimicry between an epitope on the Epstein-Barr Virus (EBY) and one of the known 
SLE autoantigens is one such example. Thus it has been proposed that exposure to 
EBV could be a triggering factor for SLE (Parks et al 2005). Similar molecular 
mimicry between infectious agents, such as hepatitis A and EBV, and AIH has been 
suggested (Vento et a11991; Vento et aI1995). 
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1.3.2 Genetic Factors 
One of the greatest difficulties in studying "complex" genetic conditions is 
distinguishing between primary associations, and secondary associations that occur 
due to genetic linkage disequilibrium. It is difficult to know whether a genetic 
polymorphism (DNA sequence variation amongst individuals) that shows some 
association with disease is actually contributing to the susceptibility, or whether it is 
just in close linkage disequilibrium with the true causative gene, in which case it may 
not be affecting the aetiology of the disease (Bametche et al 2005). 
The clustering of different autoimmune diseases in families indicates possible shared 
genetic backgrounds and mechanisms of disease (Ueda et al2003). This is supported 
by the apparent sharing of autoimmune susceptibility loci amongst human 
autoimmune diseases and across species (Becker et al1998). The degree of 
clustering is often estimated by the relative risk that the sibling of a patient has of 
developing the same disease, compared to the general population risk for that 
particular disease. It is estimated that for siblings of affected individuals with 
autoimmune disease, this relative risk ranges between 6 and 100 (depending on the 
specific condition) meaning that they have a 6- to IOO-fold higher risk of developing 
autoimmune disease than the general population. However, these figures seem to 
differ substantially between population groups for each condition (Vyse and Todd 
1996). 
One of the difficulties in defining the exact genetic components involved in 
"complex" genetic diseases is the ability to correlate the various components of the 
clinical phenotype with the different factors that influence it. The factors influencing 
the clinical phenotype are also difficult to identify in the first place (Bametche et al 
2005). The risk conferred by any individual susceptibility allele could be very low, 
but, when combined with other susceptibility loci and possible environmental 
factors, the ability to cause disease increases (Vyse and Todd 1996). For this reason, 
identifying disease genes or polymorphisms in autoimmune diseases has proved very 
difficult (Vyse and Todd 1996; Gregersen 2003). Where specific genetic 
associations with autoimmune disease are suspected, they may be validated through 
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the repetition of defined genetic studies by independent investigative groups using 
similarly defined cohorts (Barnetche et al 2005). 
1.3.2.1 HLA Haplotypes in Autoimmunity 
Genome-wide scans have repeatedly indicated an association of the chromosome 
region 6p21.3, containing the highly polymorphic MHC class II HLA region with 
several autoimmune conditions such as IDDM, SLE and AIH (Kristiansen et al 2000; 
Krawitt 2006). Certain HLA haplotypes may have either a disease susceptibility or 
protective effect in a given population. Finding these associations is often difficult 
due to the strong linkage disequilibrium that exists between genes of this region. 
Nevertheless, a number of associations have been identified (Undlien et al2001). In 
SLE, HLA-DRB1*0301 (DR3) is associated with disease in Canadian patients while 
the DR1, 6 and 7 alleles appear to have a protective effect. The HLA-DQA1, DQBl 
genes, as well as the DR3, 4 and 9 alleles are important in susceptibility to IDDM, 
while DR3, 4, 7 and 13 is associated with disease in AIH (see section 2.3; page 24). 
DR4 is also the major susceptibility allele for RA in caucasians (white individuals of 
European ancestry) (Undlien et al 2001; Gladman et al 1999 Gebe et al 2002). The 
DQA1*0501 and/or DQB*0201 genes are also associated with celiac disease in 97% 
of cases, compared to about 40% of controls (periolo and Chemavsky 2006). 
The precise mechanisms through which the MHC class II region confers 
susceptibility to autoimmune diseases are constantly being investigated (see section 
2.3; page 24). Also, as discussed earlier, the HLA region alone does not account for 
the entire genetic component for predisposition to autoimmune diseases (Kristiansen 
et al2000). 
Genome-wide scans of families with more than one affected individual, and affected 
sibling pairs have showed several, rather large loci, associated with different 
autoimmune conditions. The heterogeneity of phenotypes, population differences, 
use of different polymorphic markers and genetic maps, and imperfect statistical and 
analytical models have mostly led to a lack of replication of results between different 
research groups (Becker 1999). However, some loci that seem to overlap between 
13 
different autoimmune conditions have been identified, and these are being studied in 
greater detail. 
1.3.2.2 CTLA4 Gene in Autoimmune Disease 
A region on chromosome 2 (2q33) appears to be a general autoimmune susceptibility 
locus. It contains three immunologically important genes that have been associated 
with autoimmune disease, namely CTLA4, CD28 and inducible co-stimulator (ICOS) 
(Veda et aI2003). These three genes are very similar in sequence and are all 
involved in immune regulation. The corresponding chromosomal region in the 
mouse is on chromosome 1 and is associated with the non-obese diabetic (NOD) 
mouse strain phenotype. In humans, associations have been investigated in, amongst 
others, Grave's disease. No associations were found in single nucleotide 
polymorphisms (SNPs) of CD28 and ICOS. However, strong linkage was found for 
the region immediately 5' and 3' of CTLA4 (Harper et a11991; Ueda et al 2003). 
The CTLA4 gene shares 78% sequence homology with CD28, suggesting that these 
genes could have arisen through gene duplication. Similarity with the mouse 
genome is 76%, suggesting that the gene duplication event occurred before 
speciation. CTLA4 encodes a 223 amino acid protein that consists of a cleavable 
leader peptide, an extracellular IgV-like ligand binding domain, a transmembrane 
region, and a cytoplasmic tail. The leader peptide is encoded on exon 1, the ligand 
binding domain on exon 2, the transmembrane region on exon 3 and the cytoplasmic 
tail on exon 4 of the CTLA4 gene (Kristiansen et al 2000). The known 
polymorphisms of the CTLA4 gene (see figure 1.4) include, amongst others: 
• a -318 CIT SNP in the CTLA 4 promoter region (Deichmann et a1 1996); 
• a +49 AlG SNP in exon 1, encoding a Threonine (Thr) to Alanine (Ala) 
substitution at codon 17 (Agarwal et al 2000), and; 
• a CTLA4(AT)n dinucleotide repeat micro satellite polymorphism in the 3' 
untranslated region (UTR) of exon 4. At least 23 different alleles have been 
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The +49 A/G polymorphism has been shown to affect IL-2 regulation, cellular 
distribution of CTLA4 and T cell proliferation response under suboptimal T cell 
stimulation conditions such as limited ligand availability (Maurer et al 2002). The 
+49 GIG genotype has been found to be associated with AIR in northern European 
and Chinese patients, 100M in Iranians and SLE in Japanese patients (Agarwal et al 
2000; Fan et a12004; Mojtahedi et al2005; Ahmed et al2001). However, no 
association was found between the +49 A/G polymorphism and SLE in Spanish and 
Korean patients (Aguilar et a12003; Hudson et a12002). 
Three other possible disease-associated variants, CT60, J031, J030 and J 027_1 
have been identified within a 6.1 kb region within the 3' region of CTLA4. CT60 
showed particularly strong association with autoimmune hypothyroidism and 
Graves' disease and to a lesser extent with 100M (Veda et al 2003). The CT60 G 
allele has since also been found to be associated with coeliac disease (Van Belzen et 
a12004). 
1.3.2.3 Soluble CTLA4 
CTLA4 exists in two forms in humans: a full length CTLA4 (flCTLA4) molecule, 
encoded by exons 1,2,3 and 4, and an alternatively spliced, soluble form (sCTLA4) 
lacking the transmembrane domain encoded by exon 3 of the CTLA 4 gene. The 
frameshift caused by the alternative splicing leads to the inclusion of an extra 22 
amino acids due to a new translational termination site 3' of the original site. 
sCTLA4, unlike its full length counterpart, is constitutively expressed by 
unstimulated T cells (Purohit et a12005) and is present in human serum. However, 
this expression of sCTLA4 is downregulated after T cell activation in normal cells, 
while flCTLA4 is upregulated. This suggests that sCTLA4 may playa more 
important role than flCTLA4 in the early stages of an immune response through its 
immunoregulatory properties (Magistrelli et al1999; Wong et al2005; Liu et al 
2003). Mouse studies have shown that sCTLA4 binds to C080/86 more avidly than 
full length CL T A4. This suggests that reduced levels of sCTLA4 may lead to 
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reduced blockade of CD80/CD86, leaving them available for T cell activation by 
CD28 (Oaks and Hallett 2000; Oaks et a12000; Veda et aI2003). 
The possibility that specific polymorphisms within and around CTLA4 might affect 
its splicing ability has been suggested by Oakes and Hallet (Oakes and Hallet 2000). 
Full length to sCTLA4 mRNA ratios have been shown to differ significantly between 
individuals with different genotypes of CT60, with a 50% lower ratio in individuals 
homozygous for the CT60 G allele. It is hypothesised that the CT60 GI A SNP may 
affect the efficiency of gene splicing in CTLA4 (Veda et aI2003). No correlations 
have been found between the -318 CIT promoter region polymorphism and sCTLA4 
serum levels in patients with SLE (Liu et aI2003). 
Serum sCTLA4 concentrations were increased in many SLE (Range: 28 to 78 ng/ml 
vs. 'virtually undetectable' in controls) and autoimmune thyroid disease (21.6± 12.3 
ng/ml vs. 5.9±5.4 ng/ml) patients compared with healthy control individuals (Oakes 
and Hallet 2000; Liu et al2003). These increases suggest that sCTLA4 inhibits 
CTLA4 function by binding to CD80/CD86 more readily than the latter, possibly 
interfering with the downregulation of T cell activation (Oakes and Hallet 2000). 
However, subsequent studies have shown conflicting data for other autoimmune 
conditions. For instance, no correlation was found between CT60 and sCTLA4 
levels in serum ofIDDM patients (Purohit et a12005) and Liu et al (2003) envisioned 
a dual role for sCTLA4 whereby it also blocks CD28-mediated T cell activation by 
competing for its ligands. The exact function of sCTLA4 remains unclear. 
One of the problems in elucidating a role for sCTLA4 is that studies on sCTLA4 
have been in patients with active or inactive disease, some of whom were already on 
treatment. For example, Liu et al (2003) compared the serum sCTLA4leveis ofSLE 
patients on different dosages of steroid therapy as well as patients on treatment and 
without treatment. Thus, there is a lack of data that compares serum sCTLA4 levels 
of patients during three important phases of disease, namely: 
• At presentation with active disease (before treatment); 
17 
Genetic factors that appear to determine susceptibility to various autoimmune 
conditions, such as the HLA region and CTLA.4, have been identified while other 
genetic factors are thought to determine susceptibility to specific autoimmune 
conditions. For most autoimmune diseases, genetic factors alone appear to be 
insufficient to trigger the autoimmune process and certain environmental factors such 
as pathogens, toxins and drugs are thought to be necessary in initiating autoimmunity 
(Mackay 2000). 
Much work remains to be done to elucidate the complex genetic components of 
autoimmune disease. Autoimmune predisposing genetic components that have been 
identified need to be investigated further in different population groups and 
autoimmune conditions. Furthermore, the role of sCTLA4 in different autoimmune 
conditions needs to be investigated. 
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Chapter 2 
Autoimmune Hepatitis and Autoimmune Hepatitis 
in Africa: Review 
2.1 Definition of Autoimmune Hepatitis and Introduction 
Autoimmune hepatitis (AllI) is a chronic hepatitis characterised by the presence of 
liver associated autoantibodies, raised serum gamma globulin levels and interface 
hepatitis with a lymphoplasmacytic necroinflammatory infiltrate on liver histology 
(Alvarez et alI999). AllI has a mean annual incidence of about 1.9 per 100,000 
population in northern Europeans with a point prevalence of 16.9 per 100,000 
individuals compared to 42.9 per 100,000 population in Alaskan natives. It accounts 
for about 5.9% of all liver transplants in the USA and 2.6% in Europe. Recurrence 
of disease after transplantation is estimated at about 27% in the UK (Boberg et al 
1998; Milkiewicz et al1999; Wiesner et al1998; Hurlburt et al2002; Czaja 2005). 
High ethnic variability in the occurrence, severity, onset of disease and response to 
therapy has been observed for AllI (Lim et al2001; Zolfino et al2002; Czaja 2005; 
Czaja et al 2(02). 
As is the case with most other autoimmune diseases, AllI shows a female 
preponderance of 4: 1 in caucasoid populations. There is some evidence suggesting 
that hormonal differences, gender specific responses, and exposure to drugs and 
toxins contribute to the higher prevalence in women. Environmental agents, 
infections and pregnancy could also playa role in triggering disease. Despite the 
definite female preponderance, there seems to be no difference in the clinical 
expression of AllI between sexes (McFarlane and Heneghan 2004; Czaja 2(05). 
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2.2 Diagnosis, Clinical Findings and Treatment 
Although not the focus of this dissertation, it is appropriate to consider some clinical 
aspects of Am. It is a heterogeneous condition and presentation of disease can vary 
widely. There may be no visible clinical signs or non-specific symptoms such as 
fatigue, or acute severe hepatitis or decompensated chronic liver failure may be the 
presenting features. The diagnosis of Am is therefore best based on the correlation 
of liver biopsy findings, positive liver associated autoantibodies, negative viral 
serology, a clinical history supportive of a diagnosis of Am, response to 
immunosuppressive therapy and most importantly, the exclusion of other causes of 
chronic hepatitis. The diagnostic criteria for Am that were put in place by the 
International Autoimmune Hepatitis Group in 1993 (Johnson et al1993) and revised 
in 1999 (Alvarez et al1999) give numerical scores to a number of biochemical, 
epidemiological, serological and clinical factors to determine the probability of a 
diagnosis of Am in a given patient. The system is important in the reporting of 
research papers but is not practical in daily clinical work, except in the setting of 
specialised liver units (Zolfino et al 2002; Czaja 2(05). 
For clinical convenience, clinicians have separated the condition into types 1 and 2. 
However, this classification is not recognised by the International Autoimmune 
Hepatitis Group, because of the fact that it does not influence the nature of therapy. 
Type 1 is the most common form and occurs in 70-80% of Am cases (Czaja 2005; 
Alvarez et alI999). It is characterised by the presence of circulating antinuclear 
antibody (ANA) and/or smooth muscle antibody (SMA). Extended spectrum 
antibodies such as antiactin antibodies, atypical perinuclear antineutrophilic 
cytoplasmic antibody (pANCA), liver-pancreas antigen (LP) and soluble liver 
antigen (SLA) may also be observed. 
Type 2 Am is characterised by the presence of anti-liver, kidney microsomal 
antibody (anti-LKM-l) and/or anti-liver cytosol 1 (ALC-l) (Krawitt 2006; Alvarez et 
alI999). In children particularly, type 2 Am may be associated with partial serum 
immunoglobulin A deficiency (Vergani and Mielie-Vergani 2(03). 
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Up to 25% of patients test negative for the standard liver-associated autoantibodies, 
but have disease that is indistinguishable from classic Alli. These patients constitute 
the cryptogenic steroid-responsive autoimmune hepatitis entity in the new 
classification of chronic hepatitis from the International Working Party on chronic 
hepatitis (Ludwig et alI995). Diagnosis of these patients relies on a combination of 
serum biochemical abnormalities, hypergammaglobulinaemia, histological findings, 
history of autoimmunity in the patient or close family members and the exclusion of 
other causes of chronic liver disease (Ludwig et al1995; Alvarez et a11999). 
It is not known whether Alli is attributable to a T HI or T H2 response as the presence 
of liver autoantibodies appears to be a secondary effect of disease, rather than the 
cause. The current and generally accepted hypothesis on the pathogenesis of Alli is 
that of an unknown environmental agent, such as a drug or virus, triggering an 
autoimmune response through molecular mimicry (see Chapter 1). Epitopes from 
hepatitis A and EBV antigens that are similar to those of liver antigens in humans 
have been investigated as possible viral triggers of Alli. The subsequent injury is 
self-perpetuating and leads to disease (McFarlane and Heneghan 2004; Vento et al 
1991; Vento et al1995; Krawitt 2(06). 
2.2.1 Assessment of Liver Disease 
The assessment of the severity of liver disease in an individual patient relies on the 
use of a combination of tests that include: 
1) The assessment of liver histopathology: 
This includes the assessment of fibrosis and inflammation! necrosis and also 
enables the exclusion of other causes of liver injury. 
2) The assessment of liver synthetic function: 
The ability of the liver to synthesise proteins is measured through serum 
albumin (ALB) levels, the production of clotting factors as reflected by the 
international normalised ratio (INR) and fibrinogen production. 
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3) The assessment of liver inflammation: 
Hepatocellular injury is measured through histological assessment and 
biochemical assessment through aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels in blood. 
4) The assessment of bile duct injury: 
Bile duct injury is reflected through histological assessment and the serum 
levels of alkaline phosphatase (ALP) and gamma glutamyl transpeptidase 
(GTT). 
2.2.2 Treatment 
Standard treatment options available for Ali include anti-inflammatory or 
immunosuppressive therapy. Treatment with corticosteroids such as azathioprine 
and/or prednisone results in a 20-year life expectancy for over 80%, while untreated 
patients with interface hepatitis generally have a life expectancy of about 5 years. It 
is therefore important to be able to distinguish the disorder from other forms of 
chronic hepatitis (Krawitt 2006; Vergani and Mieli-Vergani 2003; Zolfino et al 
2002). A combination of prednisone and azathioprine is currently the preferred 
treatment for Ali rather than prednisone or azathioprine alone, as it is associated 
with a lower rate of drug-related side effects. However, individual clinical 
assessments and regular follow-ups are necessary to determine the treatment of 
choice (Czaja and Freese 2002). Other treatment possibilities under investigation for 
severe disease include cyclosporine, tacrolimus, methotrexate and mycophenolate 
mofetil. 
The use of corticosteroids in very mild Am may be excessive and possible drug-
related side effects need to be weighed against the benefits of treatment. Patients 
with cirrhosis, as well as menopausal and older patients may have an increased risk 
for drug-related complications. During pilot treatment studies, Budesonide and 
ursodeoxycholic acid have shown promise as agents for future treatment of mild Am 
(Czaja et al2oo0; Czaja and Freese 2002). 
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Treatment is generally considered inevitable in cases where serum AST levels are 
more than lO-fold the upper limit of normal, or more than 5-fold the upper limit of 
normal with gammaglobulin levels more than twice that of normal. Another 
indication for treatment necessity is the presence of bridging or multi acinar necrosis 
on histologic examination (Czaja and Freese 2(02). 
Conventional treatment regimens for adults start with about 50 mg azathioprine 
daily, together with 30 mg prednisone in the first week of treatment and reducing it 
weekly thereafter until a dose of about 10 mg prednisone per day is reached (Czaja 
2(05). 
The treatment of children with Am is not much different to that of adults, even 
though they are prone to much more severe disease. Initial treatment with daily 
doses of 2 mglkg prednisone and early introduction of azathioprine is generally 
effective (Czaja and Freese 2(02). 
Treatment efficacy is affected by age, geographical regions, population groups and 
genetic predisposition. About l3% of Am patients do not respond to conventional 
corticosteroid therapy. Upon azathioprine failure or toxicity, patients are treated with 
high prednisone or changed to alternative agents such as cyclosporine or tacrolimus. 
In prednisone failure or toxicity, alternative agents that have been used successfully 
include mycophenolate mofetil and azathioprine monotherapy. Where there is 
treatment failure with advanced liver disease, liver transplantation may be necessary 
(Czaja et al 2005; Czaja and Freese 2(02). 
2.3 Genetics of AIR 
Type I Am is associated with the HLA-DRB1 *0301 (DR3) or the HLA-DRB1 *0401 
(DR4) serotypes in northern European and North American patients. The HLA-DR3 
haplotype is associated with early-onset, severe Am, while HLA-DR4 associates 
with milder disease that has a better response to corticosteroid therapy (Krawitt 
2006; Strettell et al1997; Lim et al2(01). HLA-DRB1 *l301 occurs more 
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frequently in type I Alli in South America, and is associated with poor response to 
therapy, while the ORB 1 * 1302 appears to have a protective effect in the same 
popUlation (Pando et al1999; Goldberg et al2001; Czaja et al2002). Susceptibility 
in Japanese patients is linked to ORB 1 *0405 (Ota et alI992). In the light of this 
data, ORB 1 has been implicated as the principle susceptibility locus for type I Alli 
(Czaja 2005). 
On the other hand, type II Alli has been associated with the HLA-OQBl *0201 
alleles in Canadian and French paediatric patients, while HLA-OR2 seems to be 
protective in northern European caucasians (Ojilali-Saiah 2004; Krawitt 2006). 
HLA-ORBI *07 has also been associated with type II Alli in Brazil and Germany. 
German patients furthermore had higher frequencies of HLA-ORB 1 *15 and HLA-
OQB 1 *06 (Bittencourt et al 1999; Czaja 1997). The lack of coherence in data from 
these different studies regarding susceptibility loci highlights the difficulty in linking 
a particular locus to the disease, and stresses the importance of defining homogenous 
study groups (Strettell et alI997). 
The a and ~ chains of the MHC class II molecule form a peptide binding groove with 
9 pockets into which antigen peptides fit, when bound to the molecule. Most of the 
polymorphisms that render the MHC such a variable region are found within these 
pockets, resulting in its unique binding patterns. HLA conferred susceptibility to 
Am has been linked to the LLEQKR amino acid motif at positions 67-72 of the OR~ 
polypeptide. It is hypothesised that low binding affinity between self antigens and 
class II HLA molecules could lead to reduced tolerance. It is thought that the 
presence of a positively charged amino acid at position 71 of the OR~ polypeptide, 
such as Lysine in ORB 1 *0301 and ORB 1 *0401 and Arginine in ORB 1 *0404 and 
ORB 1 *0405 haplotypes, may be one of the main risk factors conferring disease 
susceptibility to Alli. The ORB 1 *1501 allele, which protects against Alli in North 
Americans and northern Europeans, has a neutral, nonpolar Ala at position 71 of the 
OR~ polypeptide. The ~71 residue is situated at the tip of the a-helix of the OR~ 
chain where it can possibly interact with both the presented antigen as well as the T 
cell receptor. It is therefore hypothesised that the more HLA molecules with 
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positively charged amino acids at position P71 that are expressed at the cell surface, 
the higher the susceptibility will be to the disease (Gebe et al 2002; Strettell et al 
1997; Czaja 2005; Doherty et alI994). 
As with many other forms of autoimmune disease, HLA haplotypes alone do not 
account for the entire genetic component of susceptibility to Am. Other 
autoimmune promoter genes, such as the tumour necrosis factor a (TNF-a) gene, the 
TCR constant p gene, the Gm immunoglobulin allotype and the CTIA4, gene have 
been associated with genetic susceptibility to Am in various studies (Czaja 2005; 
Bittencourt et alI999). 
The CTIA4 +49 G allele was found to be associated with type 1 Am in northern 
European caucasians. In the same population, the CTIA4 G/G genotype was found 
to be associated with higher mean serum AST levels and a higher frequency of 
antibodies directed against thyroid microsomal antigens. Work on French and 
Canadian children showed an a~sociation of type I Am with the +49 A allele, while 
Bittencourt et al (2003) found no association with the CTIA4 +49 NG 
polymorphism and Am in a Brazilian cohort (Agarwal et al 2000; Djilali-Saiah et al 
2(01). 
This discrepancy in the CTIA4 +49 data could indicate that either: 
• there is a difference between the genetic predisposition of paediatric and adult 
forms of Am, as was indicated for HLA association in Argentinean patients 
(Pando et alI999); or 
• genetic predisposition to Am varies between population groups; or 
• the CTIA4 +49 NG polymorphism is simply in linkage disequilibrium with 
the true disease-associated genetic factor; or 
• the initial association of the CTIA4 +49 G allele with type 1 Am by Agarwal 
et al (2000) could have resulted from a co-occurrence of Am and autoimmune 
thyroid disease, as was suggested by Djilali-Saiah et al (2001). 
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Thus, further work on the role of the CTIA4 +49 NG polymorphism in other 
population groups may help to shed light in this regard. 
Djilali-Saiah et al (2001) also showed that there is an association between the CTIA4 
AT(n) microsatellite in the UTR 3' of exon 4, which may affect mRNA stability, 
and Am. The -318 C allele was found to be significantly increased in Chinese 
patients with Am (Fan et al2004). There is no published data investigating the 
CT60 G/ A polymorphism 3' of the CTIA4 gene in Am. 
2.4 AIR in Africa 
Although Am clearly occurs in non-caucasian populations (Zolfino et al2oo2; 
Hurlburt et al2002; Lim et al2ool), the disease is poorly documented in Africa, 
giving rise to the impression in the literature that the disease is rare on the African 
continent. Most research on Am to date has been on European caucasian or 
Japanese patients. However preliminary studies on small groups of non-caucasian 
patients in the UK (Zolfino et al 2002) and the USA (Lim et al 2001) have indicated 
possible differences between caucasian' and non-caucasian patients with regard to 
Am. Work done on a small cohort of non-caucasian patients in the UK suggested 
that disease in these patients tends to be more severe, occurs at a younger age and 
responds less well to standard immunosuppressive therapy, than in their caucasian 
counterparts. A high proportion of these patients also had underlying 
cholangiopathy, compared to the non-caucasian Europeans (Zolfino et al2002). A 
study by Lim et al (2001) showed that 85% of African American Am patients had 
cirrhosis at presentation, compared to 38% in a caucasian cohort. Their findings also 
suggested higher bilirubin levels in African American Am patients and a need for 
higher prednisone doses in order to maintain remission (Lim et al 2001). It is 
important to note that these studies were done on small groups of patients living in 
the UK or America. There are no comprehensive studies of Am in southern Africa 
that document its clinical, immunological and histopathological features. 
Similarly, the genetic basis of Am in southern African populations has not been 
studied. Genetic susceptibility seems to vary between population groups and it is 
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therefore important that genetic, environmental and cultural differences be 
investigated. Preliminary data from our Centre (the UCT-MRC Liver Research 
Centre at Groote Schuur, Cape Town) failed to show genetic association between the 
CTIA4 exons 1,2 and 3 with SLE or Alli (Hairwadzi et al2002; Mda et al2002). 
However, the promoter region, exon 4 and the UTR 3 I of the gene was not 
investigated in these studies. 
2.5 Summary 
Alli is a heterogeneous condition in terms of clinical features, presence of 
autoantibodies, genetic predisposition, disease activity and response to treatment. 
There is a definite female preponderance in Alli and treatment currently relies 
mainly on immunosuppressant therapy. Although HLA haplotypes have been shown 
to playa role in genetic susceptibility to disease, other genetic factors such as CTIA4 
gene polymorphisms are currently of interest. There is discrepancy between results 
from different population groups, regarding the association of CTIA4 
polymorphisms with disease. This might imply a need to investigate the genetics of 
the condition in the context of ethnicity. Most studies on the genetics of Alli have 
focussed on American and northern European caucasoid populations. 
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Chapter 3 
Research Questions, Aims and Objectives 
3.1 AIR in the MRC-UCT Liver Clinic 
Am constitutes 34% of the chronic hepatitis patients that are seen at the MRC-UCT 
Liver Research Centre clinic at Groote Schuur Hospital, Cape Town, and a 
significant proportion of the clinical work load. Historical data (over 30 years) from 
this clinic shows that Am affects all races and age groups with a female 
preponderance. Furthermore, our local experience shows that the disease occurs 
frequently in the non-caucasian populations (57%). Twelve percent of the clinic 
cohort of Am patients are indigenous black Africans. Most of these black patients 
have advanced liver disease with 46% being cirrhotic at presentation (Hairwadzi et al 
1999). It is difficult to separate late presentation, from a more aggressive disease 
with more severe injury, due to socioeconomic and health care access factors. Data 
from North America suggests that Am in the non-caucasian populations is a more 
aggressive disease that requires higher steroid doses (Lim et al2001). 
There are a number of current studies focusing on Am within the MRC-UCT Liver 
Research Centre. The work undertaken in this study is one such study, and focuses 
on the role of CTLA4 in Am in defined ethnic groups. 
3.2 Background: Introduction and Previous Studies 
As outlined in the preceding chapters, CTLA4 is important in the regulation of T cell 
activation by competing for the same ligands as the co-stimulatory molecule, CD28. 
Known polymorphisms within the CTIA4 gene have been reported to be associated 
with several autoimmune conditions, including AIH (Kristiansen et al 2000; Fan et al 
2004; Agarwal et al2ooo; Mojtahedi et al2005; Ahmed et al2001; Ueda et al2003; 
Van Belzen et al2004; Djilali-Saiah et al2001). However, there is conflicting data 
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regarding the role of these CTIA4 polymorphisms in autoimmune disease and studies 
in some population groups have shown a lack of association of these polymorphisms 
with disease (Heward et al1998; Ahmed et al2001; Aguilar et al2003; Hudson et al 
2002; Bittencourt et al2003). 
A serum soluble form of CTLA4 (sCTLA4) exists and is thought to have a similar 
immunoregulatory function as the full length CTLA4 (flCTLA4). However, unlike 
flCTLA4, sCTLA4 is constitutively expressed on unstimulated T cells and may be of 
importance in the early regulation of T cell activation. It has been suggested that the 
efficiency of the splicing of the CTIA4 gene to produce the soluble form of the 
protein is influenced by polymorphisms in or around this gene (Ueda et al2003). 
Furthermore, Oakes and Hallet (2000) showed that patients with autoimmune thyroid 
disease had elevated levels of sCTLA4. The role (or lack thereof) of sCTLA4 in 
AIH remains to be elucidated. 
Finally, results from preliminary studies on very small cohorts of non-caucasian 
northern European and American patients suggest that these patients present with 
more severe disease at a younger age, and require more aggressive therapy. 
However, further investigation in such groups needs to be performed. 
3.3 Aims of the Study 
The aims of this study were: 
• To investigate CTLA4 gene polymorphisms in AIH patients in South Africa 
and, if present, to examine whether such polymorphisms correlate with 
clinical disease. 
• To evaluate possible differences in clinical disease and genetic susceptibility 
to AIH amongst various locally represented ethnic groups. 
• To investigate a possible role for sCTLA4 in AIH andlor in the disease 
progression. 
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• To assess the severity of AIH and how this correlates with CTLA4 
genotypes, sex, ethnicity and age of onset. 
3.4 Objectives of the Study 
The objectives of this study were: 
• To assess the frequency of known polymorphisms in and around the CTLA4 
gene (-318 crr, +49 A/G and CT60 G/ A) in South African patients with 
AIH, and to compare this data to that of ethnically matched control groups. 
• To screen the CTLA4 gene for any novel DNA sequence variations in a 
South African cohort of AIH patients who had family members with either 
AIH or any other form of autoimmune disease. Both affected and unaffected 
family members who were available and gave consent were studied. 
• To investigate possible associations or correlations of any polymorphisms in 
the CTLA 4 gene with clinical disease in the various ethnic groups of South 
African AIH patients. 
• To investigate sCTLA4 serum concentrations in South African AIH patients 
at presentation with AIH (before introduction of treatment) and during 
controlled disease (on treatment). 
• To assess the severity of AIH by analysis of ALT, ALB and INR indices in 
order to investigate how disease severity correlates with CTLA4 genotypes, 
sex, age of onset and ethnicity. 
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Chapter 4 
Materials and Methods 
4.1 Selection of Study Cohort and Isolation of DNA 
4.1.1 Study Subjects 
A potential cohort of 122 Type 1 AIH patients from the VCT Groote Schuur Liver 
Clinic database was selected for use in screening the CTLA4 gene for possible 
di~ease-associated polymorphisms. This cohort included all patients for whom DNA 
samples had been collected over a two year period prior to the study. Diagnosis of 
AIH in these patients was based on clinical data, autoimmune serology, liver biopsy 
and response to therapy, as has been described by the AIH working group (Johnson 
et al 1993). The severity of disease in these patients was determined, where possible, 
by measuring three important indices. Firstly, the degree ofliver inflammation was 
assessed using the alanine aminotransferase (ALT) levels of the patient. Secondly, 
the ability of the liver to produce proteins was determined by measuring the albumin 
(ALB) concentration in the blood. Finally, the ability of the liver to maintain normal 
blood clotting was determined using the international normalised ratio (INR). The 
cohort used comprised 25 black African (6 male; 19 female), 34 caucasian (8 male; 
26 female), 44 mixed ancestry (7 male; 37 female) individuals and 15 individuals of 
Asian (4 male; 11 female) descent, and was termed the "study cohort". A description 
of the liver biochemistry, sex, ethnicity and age of onset of the patients that 
participated in this study cohort is presented in Appendix A. 
A second, family-based cohort included a subset of 12 of the above female patients 
for whom DNA from consenting family members was available (see Appendix A *), 
and was termed the "family-based cohort". In all cases, family members were fIrst 
degree relatives, with the exception of patient 974 where the family members were 2 
uncles on the mother's side. This cohort was chosen in order to have a basis for 
studying a potential disease-association of any novel sequence variations identifIed. 
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Thus, family members with AIH or any other form of autoimmune disease, as well as 
unaffected family members who gave informed consent, were included in this part of 
the study. 
Furthermore a second, sub-cohort was assembled from the study cohort for use in 
sCTLA4 enzyme-linked immunosorbent assay (ELISA) analysis. This group 
comprised 18 patients who had presented with severe, acute fulminant AIH, with 
active disease at the time of blood collection. Two blood samples were collected 
from these patients. The first was taken at presentation with AIH, before 
commencement of treatment and the second was taken at a follow-up session, 3 
months after treatment commenced. 
A control cohort of 57 hepatitis B virus (HBV) infected patients representing all the 
ethnic groups of which the study cohort was comprised, was collected for 
background population studies during the time period of this study. These included 7 
black African (3 male; 4 female), 2 caucasian (1 male; 1 female), 42 mixed ancestry 
(21 male; 21 female) individuals and 6 individuals of Asian (5 male; 1 female) 
descent. This group was chosen as the most suitable controls for our study, based on 
the fact that detailed clinical reports for these individuals were available that 
confIrmed a lack of symptoms for AIH and/or any other form of autoimmune 
disease. However, the group represents the ethnic, age and sex demographics of the 
HBV patients at the UCTIMRC Liver clinic at Groote Schuur hospital, rather than 
the true population demographics of the region and therefore differs from the study 
cohort in this regard. This will be discussed further in chapter 6. 
Informed, verbal consent for this and other related AIH studies was obtained from all 
participating individuals, prior to sample collection. Ethical approval for this study 
was obtained from the University Research Council Research Ethics Committee 
(Reference number: 090/99). 
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4.1.2 Isolation and Storage of DNA 
On receipt of blood samples in the laboratory, each patient was coded and family 
information recorded prior to involvement of the researcher. These codes were used 
in the study, instead ofpatient information. In this way the study was blinded to the 
researcher, thereby preventing biased interpretation of results. 
DNA was isolated from 2.5 m1 whole blood, using the Wizard Genomic DNA 
Purification kit (prom ega, Madison, USA) as per the manufacturer's protocol (see 
Appendix B) and quantified with the GeneQuant RNNDNA Calculator (Amersham 
Pharmacia Biotech, Uppsala, Sweden). The purity of DNA was assessed on the basis 
of the optical density (ODh601280ratio obtained. Only DNA with an OD2601280 ratio 
of 1.5 - 2 was utilised. 
DNA samples for long-term storage were kept at -80°C. Aliquots of the DNA 
samples were diluted to 100 ng/JlI and stored at 4°C for the duration of the project. 
4.2 Primer Design and Polymerase Chain Reaction 
(PCR) 
The genomic sequence of the CTLA4 gene was obtained from both the National 
Centre for Biotechnology Information (NCBI) website 
(http://www.NCBl.n1m.nih.gov)and the ENSEMBL website 
(http://www.ensembl.orglindex.html) and annotated using information from both 
these sites regarding SNPs, intron-exon boundaries, start and stop codons as well as 
dinucleotide repeats (see Appendix C). 
PCR primers were designed based on the genomic sequence described above, using 
Primer3 (http://frodo.wi.mit.edy/cgi-bin/primer3/primer3 www.cgi) for the 
amplification of the first three exons of the CTLA 4 gene as well as the translated part 
of exon 4, the promoter region and an UTR downstream of exon 4. The latter 
amplicons (amplification fragments) included the site for the CT60 G/A 
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polymorphism (NCBI accession number: rs3087243). Primer3 allows for the 
specification of certain parameters such as primer length, GC content and melting 
temperature. Oligo Calculator was used to confirm the GC content and melting 
temperatures (http://www.pitt.edyl~rsup/OligoCalc.html). At least 60 bp of the 
flanking intronic regions were included in the amplicons, as splicing regulatory sites 
commonly occur within 40 bases from the exon splice sites. In addition, to assess 
primer specificity for the target sequences alone, the primer sequences were 
compared to the rest of the human genome, using the Basic Local Alignment Search 
Tool (BLAST) (http://www.NCBLnlm.nih.govIBLAST).Primers were 
manufactured by Integrated DNA Technologies, Inc (Coralville, USA). Further 
criteria for the design of primers, as well as primer sequences and information, are 
listed in Appendix D. 
PCR reactions were performed (see Appendix E) and the products subjected to 6% 
polyacrylamide gel electrophoresis (PAGE) (see Appendix F) to assess the PCR 
products for purity. 
4.3 Investigation of Previously Reported CTLA4 
Polymorphisms in AlB Patients 
Pure PCR products were obtained as described above (see section 4.2; page 34). 
4.3.1 Restriction Enzyme (RE) Digestion 
RE digestion is a cost-effective method commonly used for the detection of 
polymorphisms within DNA fragments. Commercially available REs recognise 
specific, short, palindromic sequences within DNA and cleave the DNA at the site of 
recognition. Where polymorphisms occur within a DNA fragment, RE recognition 
sites may be created or destroyed, enabling restriction map analysis to be performed. 
Once an enzyme has been identified for use in screening for a particular 
polymorphism or mutation (rare DNA sequence variations that are often disease-
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causing), the DNA fragments to be screened are incubated with the enzyme and the 
resulting fragments analysed by electrophoresis. 
Hence, in this study, assays were developed to screen all patient and control cohorts 
for previously reported polymorphisms (see Appendix G.I). RE maps for wild type 
and polymorphic DNA fragments were constructed using Carolina Webcutter 
software (http://www.carolina.comlwebcutter/carolina.asp) and are shown in 
Appendix G.2. 
The -318 CIT polymorphism destroys an Mnll site in the CTLA4promA amplicon 
(see Appendix G .2.1), while the +49 AlG polymorphism creates an Ital site in exon 1 
(see Appendix G.2.2). In the UTR 3' of exon 4, the CT60 GI A polymorphism 
destroys an HpyCH4IV site (see Appendix G.2.3). 
4.4 Polymorphism and Mutation Screening of the CTLA4 
Gene 
The CTLA4 gene was screened for possible disease-associated polymorphisms and/or 
mutations in the 12 patients from the family-based cohort. 
4.4.1 Polymorphism and Mutation Analysis 
4.4.1.1 Denaturing High Performance Liquid Chromatography (DHPLC) 
Analysis 
On successful amplification of target sequences of the CTLA4 gene, DHPLC 
screening of exons 1,2,3 and 4a, as well as the promotor region (promA), was 
performed with the Transgenomic WAVE Nucleic Acid Fragment Analysis System 
(Transgenomic Inc., Omaha, USA) at the ucr Division of Human Genetics, Cape 
Town, South Africa (see Appendix H.1). 
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DHPLC under partially denaturing conditions is a highly sensitive and cost-effective 
method used for the separation of DNA based on size, sequence and temperature 
differences. This system relies on a form of reverse phase ion-pairing liquid 
chromatography to elute DNA at specific temperatures for the subsequent detection 
of heteroduplexes. 
The stationary phase of the WAVE system consists of a separation cartridge 
containing a matrix made up of hydrophobic, electrostatically neutral, polysterene-
divinylbenzene (PS-DVB) co-polymer beads that are unable to bind DNA on their 
own. When treated with a positively charged ion-pairing reagent, 0.1 M 
Triethylammonium Acetate (TEAA), the cartridge matrix is able to bind the 
negatively charged phosphate backbones of DNA molecules. TEAA acts as a 
bridging molecule for the indirect binding of DNA to the beads (Xiao and Oefner 
2001). 
The mobile phase of this system refers to the TEAAlacetonitrile buffer needed to 
elute the DNA from the cartridges (see Appendix H.l.l.2) by breaking the 
hydrophobic interactions between the PS-DVB beads and the TEAAlDNA (Taylor et 
al1998). 
DHPLC relies on a form ofheteroduplex analysis for the detection of even single 
base changes in a DNA fragment. When a mutant DNA fragment, mixed with a 
corresponding wild type sample, is denatured and allowed to reanneal, the sample 
fragments form complexes called heteroduplexes. This heteroduplex formation is 
due to the non-complimentary nature of the mutant and wild type DNA at the site of 
the DNA sequence change (see figure 4.1). Where no sequence alterations occur in 
the sample DNA, only homoduplexes will form. The formation ofheteroduplexes 
renders a double stranded DNA fragment less stable than homoduplex fragments 
under partially denaturing ion-pair reversed-phase liquid chromatographic conditions 
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Figure 4.1 Schematic representation of heteroduplex formation during hybrldisation 
[Adapted from Taylor et al 1998]. 
DHPLC requires the use of wild type (polymorphism- and mutation-negative) DNA 
samples. These were obtained from individuals with no clinical presentation of AnI 
or any other known form of autoimmune disease. The relevant sections of DNA 
were amplified and the PCR products sequenced to ensure homozygosity. PCR 
products from each affected individual were mixed with wild type PCR product in a 
I: I ratio. This step is essential for the detection of homozygous changes in affected 
individuals, as it provides a wild type allele for the formation ofheteroduplexes. 
Where polymorphisms were identified in amplicons through RE digests, wild type 
samples were substituted with controls that matched the sample at the particular 
allele, in order to prevent interference with detection of novel changes. 
The mixtures were heteroduplexed and screened as described in Appendix H.I. 
Homoduplex controls were included in every experiment, consisting of only wild 
type DNA for comparison with samples and effective detection of all heteroduplexes 
generated. 
DHPLC data were analysed using the W A VEMAKER ™ Software (Transgenomic, 
Omaha, USA). Peaks that resulted from DHPLC analysis of sample DNA were 
compared to that of the wild type homoduplex control samples included in each 
experiment. Theoretically, samples that form homoduplexes will result in two peaks 
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(although only one is generally observed), while heteroduplexes can result in as 
many as four peaks. Where the resulting chromatogram patterns and/or number of 
peaks differed from that of the wild type control, samples were further analysed. 
4.4.1.2 Single Stranded Conformational Polymorphism (SSCP) Analysis 
Due to the small amplicon sizes ofpromA (372 bp) and exon 3 (367 bp), SSCP 
analysis could be performed in order to verify the DHPLC results obtained for these 
amplicons and/or detect any mutation or polymorphism not detected by WAVE (see 
Appendix H.2). 
SSCP is an efficient method often used for the detection of single base substitutions 
in small fragments of DNA. The electrophoretic mobility of single stranded DNA is 
dependent on both size and sequence. This is based on the fact that single stranded 
DNA fragments form specific secondary structures while moving through a non-
denaturing gel. Small DNA molecules differing by even as little as one base take on 
different conformations and migrate at different speeds in a non-denaturing 
polyacrylamide gel (Orita et al 1989; Sheffield et al 1993). 
PCR products were subjected to non-denaturing MDE-SSCP in the presence and 
absence of glycerol. Glycerol acts by lowering the pH of the gel for better detection 
of larger fragments (Kukita et al 1997). 
4.4.2 Sequence Analysis 
Relevant PCR products of DNA used as wild type controls for DHPLC and SSCP 
analysis, as well as samples that showed aberrant mobility shifts on SSCP or DHPLC 
analysis were subjected to direct sequencing, to determine the precise sequence 
variations. 
PCR products (50 - 100 Ill) were purified for sequence analysis (see Appendix I) 
using the GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences, 
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Buckinghamshire, UK). Purified samples were then sequenced in both forward and 
reverse directions on an ABI 3130 XL DNA automatic sequencer using a Big Dye 
t~rminator cycle sequencing kit, by the University of Stellenbosch Genetics 
Department, Stellenbosch, South Africa. Sequence data were collected and analysed 
using BioEdit Sequence Alignment Editor Version 5.0.9.1 (Tom Hall, North 
Carolina State University, USA). To ensure that the software did not overlook any 
heterozygous changes, sequence electropherograms were also analysed for visible 
sequence alterations. 
For the detection of homozygous sequence changes, the computer software Sequence 
Manipulation Suite (SMS) (Paul Stothard, Copyright © 2000) was used to reverse 
compliment all reverse sequences generated. These reversed sequences were then 
aligned with Genbank data (http://www.NCBI.n1m.nih.gov) and forward sequences 
generated, using BioEdit. BioEdit uses a form ofClustalW 
(http://dot.imgen.bcm.tmc.edu:93311multi-align/Qptions/clustaiw.html) for aligning 
sequences. 
4.5 Serum Soluble CTLA4 (sCTLA4) Quantification 
In order to compare the protein concentrations of sCTLA4 in the blood serum of 
patients at various stages of their disease, relevant blood serum samples were 
obtained (see section 4.1.1; page 33) and ELISAs performed. 
Blood samples were collected and allowed to clot before centrifuging at 3,000 Xg for 
5 min. All serum samples were stored in aliquots at -80°C and repeated freeze-
thawing was avoided. 
Samples that had a visible precipitate were clarified by centrifugation before 
analysis, and those that were grossly haemolysed were excluded from the study. 
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4.5.1 ELISA 
Concentrations of sCTLA4 protein in the blood serum of AIH patients at various 
stages of disease, were measured using the Human sCTLA-4 ELISA kit (Bender 
MedSystems GmbH, Vienna, Austria) according to the manufacturer's protocol (see 
Appendix J). 
Sandwich ELISAs are a form of immunosorbent assay commonly used for the 
quantitative detection of specific proteins in test samples such as blood serum. 
Microwell plates are coated with a monoclonal antibody directed against the desired 
protein (in this case, anti-sCTLA4 monoclonal antibody). Serum is then added to the 
wells and the protein of interest allowed to bind to the antibody in the wells. A 
second, biotin conjugated capture-antibody directed against the same protein is 
added, "sandwiching" the protein between two layers of antibodies. After washing 
the sample wells to remove any unbound biotin conjugate, streptavidin horse radish 
peroxidase (HRP) is added which binds to the biotin conjugated antibody. The HRP 
gives a colour product in the presence of a substrate that can be quantitated by 
measuring the absorbance at 450 nm. Protein concentrations are determined with the 
use of a standard curve produced using known protein concentrations. 
4.6 Statistical analysis 
All data was sent to a Medical Research Council (MRC) statistician for statistical 
analysis. Numerical parameters, such as age at diagnosis, serum ALT activity, serum 
ALB and INR were compared between groups using the Wilcoxon-Mann-Whitney 
test. Assessments of associations between pairs of categorical variables, such as 
ethnic group, sex and genotype, were performed with the Fisher's exact test. The T -
test for paired observations was used to investigate possible trends in ELISA data. P-
values ofless than 0.05 were considered significant, while P-values ofless than 0.0 I 
were considered highly significant. 
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werr no Slgnificanl differences In Ihe ijenQlyple tp "" 0 (281) and Ilielic (p 00679) 
frequenclcs or AO' paJlenl5 CO!I1parcd 10 thai orthe comrol cohol1. as illu51n1lcd by 
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• • ... 4 
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\ , 1\ 
Fl&u", 5.1 ~uell« ft«IroPMfOlr.",S '''_"'I lbe f_ant wquentft of prolUA_ 
The 1"*'1OrI orlhe -11' poI}~ .. 1DIbal.:d ~ am:J\<o'5 
A: 'n.: .J 18 ",id type (-JI R C/(') ,;unpIt: I/SQf lIS toJlnlI 
0 , Sample NH9IO. bcI:~(-}11I C1D1Or !he-ll' pol)~_ 
C: ~,plc NH"55, I>cmo1:)"lOUS posl1m: (-)18 Tin for !he -lIS pol)'rIIDI)lhwn 
•• 
~.J.l /III/ diCest 
In wild Iype (Ti..A-I _ I ampllCOftl, lbe llE IIfll c.utJ lhe 443 bp hgmenlll 
poMlOn 271 , resuhma In IWO lfa&mmts (In bp and 271 bp) The"'9 AIG 
po/ymorphmn tJ"Qlet In IIai dijestlOft AIle III J'O'Iuon 296 0( lhe 001'1 1 Imphcon. in 
_ddlllOI1IO lhe ClUSl,"I c.unll'8 sne III po$IllOn 271 , resuhtn& In Iwee lTagmenis (2S 
bp. 1"7 bp and 271 bp) F'lSUfC S S IiluMrales lhe blnd1ll8 p.lllcms obKrvo:d IRet 
JIai dlgesllOn In 9 Plbems trom lhe IlUdy rohon Figure S 61hov.-J lhe DNA 
" 
MIq\Ience$ repre:5el1WlVc or .DdlViduals that arc wdd type. he!erozygOUJ and 
homoqsous. respectively. forl/le poIyTnOl'phisrn.1 lhe ~49 Iocul. 
1 1: J" 5 (, 1 8 , 10 II 11 13 
""'b, - - _ 
JOOb,. --~~ 
lOObp --_ 
Fit""" 5.5 6"'\. PACt: cel sIIo";n, ',,,J dim l prod..:u iII !J OSA •• mplcs of I"~ fonlrol 
fOlKIn. ~ 1 _ "". I~ fIIOI«ular .. .: .... nQn.er and lane 2 .. WI 
unc'\Il o:w. , PCR produa t~3 bpI L.- 12 WQ&aIQSII ilwMmaous posIu,c 
rontroI, ...... qO·Gj and "'0 bandlilft obKJ\cd 1",1 bpllnd H I bp Aooth!:. 
hIod ohac l~ lip "' .... pea .. -d DIIc 10 I'*" ANi,..lC • III ""'.....,.. OIIIlu •• d 
IoU!: I ~ ""ns. homol\J(lMS fIt'PI" t mnlrol C~"''' NA, "lth 1\\0 \~,bIc 
b.lndI g( ~ m bp and 171 bp TIle- -..pk III l.auc o,l • ~ ..... 
pos."C: (Qf IhI: Jlo"~m u....~. II. I . 10 ~nCI 'I CIQf1Wa .......... W'._ 
t-N" A GI~c:.. "hole....,. 1 "'and 7 art ,\lId .... p.: 
Oftnc 116 A'" pal~nu kftened ~lIh 11m. 43~"e"e NA (", ... ). 52 wee AIO (.5'.) 
and ' 6 0'-'.) ~cn GfG Oflnc 56 controls IIC".fCIelll'd, 22 ~erc NA (l9'Y.). 21 wef'e 
AIG (311" .... ) and IJ weuGlG {2J%) There WCfC no S/SIUrlCafll dilTerences.n Ibt 
.genot)'Jl4(: (p 0 JOll) and .Ikhe I.P 0 .J04) ddrn"bullont of Allf pel ,ena 
romparallO!hat of lhe CJOnlrol cohort as dlUJIrlllcd by IhcJRp/l. In figure ~ 7 
.. 
c • • • • , c • ~ 
I 1\ 
r"u~ 5,6 Srq~n(e dr;ctroPMl'1IlfllTIS slto .. -inil ihe ro .... ud !leq1l~lICa OrC11A-I 
UOII I. 1'hD .,...II(XI of !he +4~ poI)morpbl5m IS ,,,,hcated bj 2fl'OI\' 
A:Tbc wild ~pc (+-19 AlA) sample used as control 
R Sample PM. hctcroqllOUS (f49 AKi) for tile: -t<I9 poIpliorptul m 
C: Sampk AC. iIomnzypiS poJItivc t-+<l9 G1G) ror IlIc ,,49 poIymOfplu .. m 
A " 
filII" s,.,. ('1",lerH toI""1n Cup," of 11. 1 RE ..,..Iylis dan. 
A; GenotlPocdlJUlbubon of tIM: ""9 IOC:U$ ,II p3llwts;mll oonuoIs 
8 AlId,t Wslribuuon ofthe .... 9 locu5 In pguenu IIIId «lCllrob: 
3.3J IIpyClI4/Vdigesl 
In wild type C'n..AJ J'lJTR amplicons. the R£ IIp}CJl4/1 ' cuts the 296 bp fl1l8menl 
at position 234. rcsulll"8 m two ITlIgmenl$ 234 bp and 62 bp, respectively The 
(160 GJA polymorphism, howcyer. results in the 1055 orille 1I/1)('/I-IW cutting Site. 
Figure ~ II i liusulIlcs the bandmg pNth:ms ob~ after IlpyCH4W digestion ill 18 
indlvidu.I,_ Figure S 9 YlowJ the DNA sequences representative orindivldual~ thaI 
" 
are wild Iype, helCI"Olygou5 and homozygous, respcclively , for lhe polymorphism al 
loc CTOO locus 
, J -I ~ (, 7 I 9 10' I I U Jj 1-1 15 1(.17 111 1920 
JOIl bp - . 
'"' bpp - _ 
"m bp -~ 
f:ij:urr 5.8 6~~ PAGE gel sb" .. ;og IIp)'CIUfV dig~1 products in IIIIlNA unlpl~ o( 
lite palient cohorl. Lm<> 1 contam5 a lOObp nlOl"",,1ar we Igh! made'T and I""" 
2(1 an uOCUI 3' lJT1I. pe R product (296 bpi ~ S, 9, 13. 14 and IX COnl.un 
samples th;>! an; homozygws POSIII,'C fOf Ihe polynJOrphlsm ((TOO NAI and 
ont} one band IS observed {296 bpi UulCS 2. J. 4 , 6, I 1. IS, 17 and 19 oontam 
hL1CfOZ)gous (CTtiO OiA) $a~IC!i and Lhr.:c baud! ofSllCS 42 bp. 192 bp and 
2% bp an: obsl:l'\'cd, ... hlle 13/1cs 7, S. 10, 12 and I Ii rcproscnts Lhe hom""~.'gOUll 
n~",: (CT60 GIG) populJUOO .... ,Ih onl) Lhe 4I bp and 192 bp bwIds prescnl 
Oflhe 117 AIH pallentS screened with IfpyCII411', 57 W!;"re GfG(4~~). 45 were 
GiA (38·4) and the remaIning 15 were AlA ( 130/.) Dflhe 57 controls ~cened. 27 
were GIG (47%). 28 were GJA (4~.) and 2 were AlA (4· ... ) There were no 
signlfieant differences in Ihe genotyp.c (p - 0 J 036) and all elic (p ~ O ~J62) 
d'sn ibul1ons uf AIH patIents compared 10 that of ille: conlrol cohon as Illustraled by 
Ihcgraphs in ti~urt' 510 
" 
A 
• . . , 
r j 
I \ I 
B • • , , , 
c 
• • • • , , , 
, ! , 
\ ~ \ , 
Fiturf 5.9 Stqutnn df,drOphuDtl'am. ~ b_i,,& 1M (_.,d IorqWlICts oflaw <.TUJ 
). UTR ampl;con, 1lw:: posUIllOl of~ CT60 poI)~,sm .. ,nd,c lled ",Ib ._. 
A; WIld I}"JK sampk: «(,,.60 OIG) 
B: Sample Nil 2116. ~Cfozyaw. (Cf60 G/A) for ~ CT60 poIymorplllsnl 








Cf60 G/A Allelic r~q~IIC:if. s 
<, A 
Fiaure 5.10 Clusle~d column ar1phs of the IIp><:nIlVRE In.lysis dilL 
A ; w olyplC dl$lribubon oflhc CT6(l IocUll to pallc:nb and controls 
B: Allehc distribution or lhe CT60 locus in p.:illenlS and rontrols 
5.4 Genotypic and Allelic Correlations 
Oiff"Cfences in genotypic and allelic fTequencu~s amongst ethnic groups were 
in,,~igated (see figure S J I) The resultant p-V3lues roc lhe Fisl'ler exact !!:SIS of 
equality oflhe proport ions of genotypes over the groups were 0 2397 for -3 18 err. 
" 
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! ' · ~ • 
c ",,~".I"n Mi"~ d ".r"" al ",,~ 
Anoe.UY 
Etll"nl" Group 
+<19 NG Allelic Frequencies 
, - '"' . ~ '" K, " , ' " " 20 ·~ , • C .. ucao'~ MI~ &<j ,.~ BII'C~ 
AI\C~tr~ 
Ethn k: Group 
I~ ·G : 
ClSQ GlA Genotypic Frequencies 
(; - 100 ." '" " .,
!I 0 40 
I' 20 .8 0 
• CilUCiIIlnn MI,oo 
Ancestry 
Asl .. , 
E1I>nle Group 
cGG !:lOA OM 
l .. _ ",~_ 
Blaok 
cno GIA Allelic Frequencies 
'"' " " " 20 , 
C"u",..mn MI. <I<1 All"" 
Anc:e&by 
Eltlnl" GIOUp 
Fi~urc ~ , II C~f1(U~'f'ir (A) and allelic (II) (rcqu ~ ndC'l Qf pub'mol'llhi_, ms Ir<un:linl: I ... CI hn it ~rou p,. [ Ik'"o IIrou!", ~I" ",d,calcd on !he X a.~ " . whik 
Ih" pctCCOII.a¥Cl' " r Ihe I.""pecl;"c groupl arc ,nd,C;\!,'tl on !no Y -3~ ' ~ 
0.2512 for +49AIG and a ~ignilicanl 0.<XX>6 fo1'cr60 GlA. Simil;uly. lherc was a 
sigllificaJlt differellc" ill allele fmjuellcics al lhe CT60 OJ A keLiS (p < 0.000 I). 
We observed thai the signifkant di ffercrx:c in the CT60 GlA polymorphism can 
probably he auribLited 10 II rclathcly high prevalence of the polymorphi~1Il ill UK" 
block group. compared!O the other groups. 
Possible gen{)(),pic frequency di ffercn~~~ between ~I':.) wert" also a~sc~sed. No 
~ignLficant differences were foun d. P·valuc~ for tlu. an: gl veil I n table 5. 1. 
Similar! y, thell' ..... ert" no sigmficant di ffcren~-.:s in wide frequenck~ for thr:'se 
polymorphism~ hetw~n <,e;\c<. 
T ~ hl .. !'. I r" hl .. "r .l"'lcr'~ uacl , ,,,,,"I " •• " Iu" r{)r .l'-.~iall{)ns b.:l .. ·<'1/ " ~""B1J" "".lI and 
_t". 
-~~-.--". ;u---.J II! err O.SJ~.j 
+-I9,vG 0.856-1 
('"T60 Gil' O.292~ 
5.5 Sc rceninJ.: for Novel PoJYlllnrphisllls 
PCR pnxiuCb from the [wehe plItlCnt ~ In the fumily hased rohort ","ere u.\-Cd In order 
10 IlCrl:Cll UOO5 1.2 and 3, a.~ ..... ell as the t(lIIlSlillcd fl'gloo of ClI.Oll.1 and tht 
promoll:r region ofthc en""" ~fl(' for r.o\"C1 DNA pol)'morphi~ms. using DI-I f'LC. 
Funllennoo. thc n::latl"cJy small product SIUS of the ,, 1;on 3 lIlld the prornA 
Ilrnphrons. 1l100c 1\ pos....,hlc \0 ronfinn lhe Dl IPLC n:~ults for 111(:1;0: 1\\0 fragments 
">' SSCP 
" 
5.5.1 DlWLC SueeJling (WAVE) 
PCR products for which dear. single bands oould be seen on PAGE, were used for 
DHPLC anal~is Figure 5 12 shows a chromatOf/J1lm oftne DHPLC analysi, 
perfClllmd on J patient samples and a \O.,ld type OOOlroi for C1U ., exon 2 
Hetemduplex pe!lks were 001 obsetved for any of these samples OvenJl, 00 /IOvel 









l i ..... tmml 
Fillure 5. 1 Z ChrOmalOllrlm r",u lr~ of lb .. dliPLe . 1I8Iyl;I.1 S7JoC for (TU~. 
non I . Th~ chromalOgr.Uns for ClCh ofthc llrn.'<l.5."\mplcs shown (NH",5~ 
NH50J and NH6\6/ an.: nOl s lgrnfit:lntL, ~Iffo:n.," frDln.:acl! OIher or from 
~ ",id I~ Ill: s:lmplc (PM~ 2) sM\\n 111 blue 
5.5.2 SSCP 
("riA ., promA and .. Kon 3 PCR fragmems were screened for possible sequence 
ctlange5 witb SSCP No DNA changes were identified wub SSCP m e:o;on) samples 
screened. 
However, in the CfLM prom A ampliOOll!l. Identical mobility sbilU (changed 
paltenl!l) wele observed fOl" 5IImple'!l N116S9. NH980 and NH983. all ofwhich were 
shown to be bdc~gous (Of tlle·J 18 err polymorphism with RE anaJysis 
Funhl::rmore. two other samples (F611PA2 and NH4SS). showed identical patterns 
Ihat differed from both tbe wild \}-pe and from The pattern menllOned above These 
two samples were both ~hown to be homozygous for the -3 18 T allele with RE 






riEu .... 5.1J SSCP resul15 ror cru.l pmn'" 'n pat ients fro.., th~ f . ... ily cohol'1. 
MQbIIIl~ shifts wc,cobsel"ro for sample.s NH9SO (lane ,0\2), NI19lIJ (lane 
AJ)!!IId "'1-1455 (lane BoI)!IIld:m: Indu:alcd h) JffQ .... 'S Lar.: 05 tOOUlins a 
ntg3llve con1n~ 11M: p:mcms <!bserved fOf the sarnpks In IlntJ A I. ,0\4, A5, 
111 , B2. 0 3 and B6 were ""'nlocal lo!h:ll of the negallvc control 
One sample from each of ihe tWO patterns observed (NH9lIO and NHJ55j ",ere 
sequenced In order to vcnf)' lhal there were no sequence \'anallQIIS, OIher than tnc 
ones mentioned above. preScTTl III these samples No novd .::hanges wefe 'delllified 
5.6 ELISA analysis for sCTL-\4 quanlificalion 
sCTtA4 oon.cenlraIJon~ 101 the 18 AI H palicrus ~lccled from the study cohort were 
successfully dClermmcd U5lng ELISA Serum samples from these pallcnls were 
(;olk .. loo aL presemBI,on Will! !lCtive dis.-ase, and again after three momhs of 
ImmunosuppressIVe Ircalmeru Tile nlllt\UfacUlrcr's reference range mdlcates thaI 
lliere IS no delectalile sCTLA4 Ie~el s fouoo in lie~hliy donors. 
" 
A)l1ltIIIard cun'c with a reg~510f\ \ aluc (R) 0(0,99 was dr:. .... n (sec figure S. I.I) 
from che 00 .... ~admgs obtamed for the sCTLA" OIandards pro"lded by the 
m.IIlutat"lurer!>. Using chl~ cun'C, the £TLA4 concentrations for e3l:h pallcnl !lCrum 
\llmplc could t-c IklermirlCd from tlJelr respoccil'C 00'<0 Il'otdmgs (sec taMc 5.2). 
The ~CTLA4 CQrK."C nlr.iIlDnS .... ere below 1.5 ng/mlll! both ~tap of d,scase for all 18 
pa\l~ntS serum ~alllpl~ qUdIlllficd Sc\cn indl\' iduah ~holli'Cd an Inc~1ISC in 
ICTLA4 concentration . .5 II di:creli.l<C, and tnc n:mainmg 6 p;nients' .... ere unchangro 
Figure ~ I ~ plotS the chanj,!c in concentl'lliion of serum ~CTLA Jf\ the 18 p;1I.",nl.~ 
frum presc nlution wllh act ivo: di!>Ca..<;(' to lhn:r months utter trellllncni There " "II) no 
~Ignificalt t chan,,'!: in ~cn..t'J CO[ICcntraliOllS Ixt"tcn 11K: \110'0 IInlC po!nu of serum 
collection (p .. O.l07). 
" 
1,, 0.:tOh 00&1'9 . 
11' .. 099 
,. 
• • • " ". 




T~blc 5.1 sl.: '1'1 ,,' " (i)"l·CIll ... ~ ti()/lS 0( ",'mp!.:"" c.;",,,,,,,lJrul0,," w~ru o.lC'l~r",,,,.d 1I~ ))l" It.: ~w"brd ,,',"e III r'l-Ute ~.I~. S:."'L'J." 1)131 a.-,' I.Ibc:Jkd .,. I 
ItI<hco)lC ~n"n '~n~)I...'" (oIk",~~1 from a p;:.uelll 31 pr1l,«,lIWllOn wnh ,I""a-c Slnla"" y. un'(1b 1~t>.::llo.:d \ ~ .... 'Cre ,cU..-,'et! all! foUo .... -"I' 
.-.t." IC><l Ih":01 ,,-.;rn.h;. uflc.- C()n\l1lCI1<:Cmc:m oI.rea. men!. 
Coocom".lion Concen.,a,ion Concen.ratlon Cone_nll.llon Concen1 ll1, lon ........ 
(1I!t'm,) 
.... ... ,-, Sample , (ng/m') S.mple I (nglml) Sample , (ng/ml) 
NHti67.1 '.00 NH 1020.1 '.00 NH 733.1 '.33 N\i416.1 0,3~ NH 901. I ,.'" 
NH 1'l67.2 ,.'" NH .020.2 '.00 NH 733.2 '.00 NH4'5.2 ,., NH 90 • .2 ,." 
NH '0041 ' .3 ' NH 26' 1 ," NH 661 , '.00 NH 1001 1 '.00 NH 933.1 ,.'" 
NH '004.2 0.92 NH 261.2 1.01 NH661 .2 '" NH 1001.2 
,.., NH 93.3.2 0.61 
NH 1023.1 0.32 NH~l , 1 ,.'" NH 336. 1 0.35 NH 320. 1 0.69 
NH. 0232 ' .00 N'1 991 2. '32 NH336.2 0.00 NH 320.2 0.19 
NH 1024 1 0.42 NH 004.1 ' .32 NH 884.1 0.43 NH BOO, 1 0,32 
NH 10242 076 NH EIfH.2 '00 NH884.2 0.39 NH BOO 2 033 
" OJ • 
~ OJ 
<- " • -• , " • .. • • " " • • ..• " • " 6 '" '" • " " , 
" 
__ NHbll __ NU 320 Nil ))6 
__ NH~1 -NHII!I~ -NH iI'.Hl 
• NH ')') I Nfl 101) 1 _ tm Ii)/}.l 
• 
• 
_ NH(,(;1 _,..fl n) 
Nil 911 Nil %.I 
Nll1U20 -1'1 11 Jon -Nil L 02~ 
Fieure 5.15 a.,ni:C In tonuntut;on of un,," iJCrI.A4 in 1M 18 p.tienls from 
prurnlalion with KI;vr di~...., to Ihr~ mOllth • • fltt IfUlmenl. 
5.7 .... ul1her Analysis Based on I'alienl Oemographics 
The patient cobon chosen for Ihi$ RUdy included .11 the p!l1IC'fl1 . from the UCT-MRC 
Liver Chnie 81 Gmoce SclIuur hospItal for whom UNA SIImples ~ ........ I.ble and of 
high enough quality for PCR ampl ification 11 wu Ihu •• ppropriate (as drfined in the 
audy objectives) to I.llllyse the groups funher, based on Je:II., age, dtwuc ICymty. 
age of ansa. .nd Clhn.Clly 
The 5ell distriboA:ion oilM cnt~ Alii c.ohort was ) 7 I (Fem.les Males) and 1'10 
SIgnificant difTn-eoca were obJen~ (p '" 0 7186) In the proporhom of females 
vnsus males .monp ~hnlf: group. <_ uoble S J) 
T~bJe S.J Geuder. by ~thuk distribution. 
1II:l('k \fri c .... Cauca~i;lI1 ) Ii '"l'<i Ann'slr}, Asia n All 
) Inll' , , 7 , 25 
htllnl~ , '1 " 37 " 9) 
,\ II " 34 " " '18 
Analysis of d:tla regarding lhe IT\C;!n age o f on'\Cl bell'. e('n >.('J[e.~ Il'\'ea!ed tN ot 
females pre)¢II1 with A Il l , on :r.·eragc, 13.47 yt:a ... hiler tha1l 1heir m.a.Ic coonterp:u1~ 
(see lable 5.4) (p = 0.0002). Funhcnnorc,,, .<ignlfieam difference W~ foond 111 Ilk' 
lIlean age, of on.~t f"nong~t C1hnk: grouP' (p '"' 0 .0236: \\'hen adjusted for ~,. p .. 
0.0102). Thi, means Ihlil the mean of 1M leaS! one groop differs signifICantly from 
another. The <i gnlflCum d ifference obSCf'.'ed wa'; tll:oI C1U(:a, tan p"ticnh from our 
study wOOrt presented with All:!. on a'·crag(". 12.78 year<; later th.an black AfriclUl, 
p"tienls (see wble SA). 
TableSA "lean ages of onset . in years. tw-I""n "«'~es and amon!:S t Nbni<' 1.!tOUps. 
mad. Caucasian ) Iiw d \\1:111 All 
i\ fri ...-an i\ nr l':S tQ 
()c.m;) (}"r;irs ) () ~ .. rs ) (,ears] (years) 
2O,) JO.') !9.6 26.K 27.3 
) 1:.1 ... 
.(7..1) cl6 l) (IS 2) 112.1) (13.4) 
'" 47.7 371 ..... 1 40.4 .. · ... mal .. (lnSt ( 14.6) (16.91 (12.2) (16.4) 
]<).9 4H 36.0 39.S 37.6 
All 
(159) (16.4) (l6.K) (14.21 ( 16.b) 
• ~~nd .. J <1<, "'."""" .., s"""'. In tn.:~ .. ~ und,,, ..... h I .... OVen:&<" ore' 
" 
5.8 Oise:lse Se\ eril)' 1\ l:trkers 
"fbc, ALT. ALB IIItd ISR ILl ... for all oor paltenu .... ~~ collected from the p:ttknl 
~ It lilt UCT-MRC thcr Omot:ll Groolt Scltuurbospilal lk'it masters ~ 
cocnlOOCll)' uStd lIS l1li IndK'lllIOCl ofthe ~'"('n l) of AIH 1-« :.«1>00 2.2). The re~u lu 
~ ~lIled:l!' mrd,~ In IlIbk 5.5 ano.Ilablt 5.6 and tnleJ\lu;artik- rangt!> (IQR) and 
P-"~1IC'!i 11ft &I\tn. TIw:o: .... ~ =t. ~iglllfH;allI dirre~nt't in tilt INR and ALB va)1.le5 
bt'!II'een elbnot grouP" III II 5'" eonfw.kn« l/'lieMll. 001 noc for ALT. Theft litre no 
)(lIh!>lICOllly Significant dlrren:non on Illest. )("~"1)' marl::tf5 bdwet'n )('xe~ 
TM hl ~ 3.5 .\ l ('d ll,n Ii. er hiocherll lsiry indi<:6 ror Ihe d ifTtrYnl t lhnk J:rotIJIS. 
AI.T 
(ha/ml) 
~« -'I) ! 
1 fIOR 
-«1.2) 









(21 ' , 35.3) 
Cli nca.~13n 
'" 185; }'-U 
1.00 





'" f 105, tl7N 
I '0 
111 , 1'11) 
35,0 
(n~.IO~1 




( I; (9) 
]'.0 





t.."<1 b!och<_r ''''''''", III .. ,,,,, __ ..r.:r- 1M. T ~ IIIICnIIIIIII'IOIIIlnMb""" ._ 
(INR In 1lIb11ll1On (AU ) 
P-.IlIue> Wl' • • ' h_ bkJ<he ..... 1r)' 1liii0.',,,, _pt cltl_ p-ro onJ ...,.., oIno1Mod ..... , 
tho> 1(r".uI_WllIllo Io;..M 
l""'''l ..... Ic: ...... _ 0IItJ1cP;d III "'""uu. ....... ,..,h naI,. 
• No","" ...,.., 
" 
I\ .I.T (hl/on l) , 
"«4')) (89.5: 372.5) 192: S2·US, 
INR ,,, 1.2 0.515) 
"«I.l) ( U15. 17) (1.1778) 
,\ 1.11 (IlL) J.I JS O.7J.lj 
"(JS-40) (28 S: 39) (28; 39) 
ll." lItorilo;""1f)" ,..a~. II ... ,..., .... ,-.nil'....., IAL n. i ... c:nu' ...... t II<JfDUlli<d noIio 
IINIt ) 0lftIJ a(humo" t AI.B t 
r -.-.I .... ~ .......... I"".. hoochom"lr)' ,""" ... ~ .... ".".~ ,,"us -' "m' c.oklOl3\ed lIS'" lhe. 
\\ ,k""" .. Ma ... ·Whu""y "''''-
I",nquarok '''''#>"''' """ratal .. tn.:lru.1IhIIn ~ median 
A possible a.~>oci:uion ~'ween age of onsa (sec' Appendix A) and ~1'('f1ly was 
iR\'csug:lled. Tllbk 5.7 SOOWli the P-\-aJues. as wcll a'i Krnda.l · $ ('I)C'fficienl of 
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6.1 Subject Selection 
Definitive diagnosis of AIH is sometimes difficult and may be complicated by the 
presence of overlapping features with other forms of chronic liver disease. Hence, 
all ofthe 122 patients in our study cohort had a diagnosis of AIH as defined by the 
International AIH group (Johnson et aI1993). Other forms of chronic liver disease, 
such as viral hepatitis, alcoholic liver disease, Wilson's disease and non-alcoholic 
fatty liver disease, were routinely excluded. All those patients who consented to the 
study during the recruitment phase were entered into a database. 
The family based cohort used in the screening of the CrLA 4 gene for novel 
polymorphisms, consisted of a subset of female patients from the study cohort for 
whom DNA and consent from family members were available. These family 
members included individuals with and without AIH, or any other form of 
autoimmune disease. This was done to enable the investigation of a disease 
association of any possible DNA sequence variations found. We were unable to 
include male patients in this cohort due to the lack of availability of sufficient 
numbers of family members for any of the male patients in our cohort. 
An inherent problem with complex genetic disease association studies is in finding 
the appropriate control cohorts. Control groups that are selected by phenotype or by 
age (hereafter referred to as "hypernormal" control groups) although controversial, 
are expected to improve the power of the study by increasing the difference in 
susceptibility alleles between the study and the control cohorts. Another option 
would be a control cohort of clear origin, such as all the individuals born in a certain 
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time period in a specified region (Hatters ley and McCarthy 2005). However, we did 
not have access to any such groups that would be appropriate for this study. 
A previously assembled control cohort that was recruited from the medical staff and 
students at Groote Schuur hospital in Cape Town, was not used in this study after 
2.3% (4 of 171) were documented to have developed autoimmune conditions. Two 
cases of autoimmune hypothyroidism were noted from the medical staff group while 
2 medical students developed inflammatory bowel disease with abnormal liver tests 
(possible primary sclerosing cholangitis) during the first 18 months following 
recruitment. This cohort had been recruited following the exclusion ofautoimmune 
diseases using an oral interview that interrogated the participants regarding the 
presence of any symptoms suggestive of autoimmune diseases. No clinical 
examination or immunological or biochemical testing for possible autoimmune 
diseases had been performed. The occurrence of autoimmune disease in 2.3% of the 
cohort, picked up during a short period of time and without active surveillance of the 
cohort, was a major concern. It questioned the value of using such cohorts without 
active, objective screening for autoimmune disease. 
Hence, we created an autoimmune disease hypernormal control group in whom AIH 
and other autoimmune diseases had been clinically and immunologically excluded. 
All patients presenting to the VCT Liver clinic with chronic hepatitis were routinely 
screened for AIH. Based on this, we managed to assemble a group of patients with 
confirmed viral hepatitis in whom other forms of chronic liver disease, including 
AIH, had been excluded, and who had no clinical or family history of any other form 
of autoimmune disease. However, the constitution and demographics of the HBV 
control group was affected by the following: 
• The short time period of recruitment for the purposes of this study; 
• The incidence ofHBV infection in the different ethnic groups in South 
Africa affecting the representation of caucasian patients; 
• The population demographics of the Western Cape Province of South Africa 
affecting the representation of black African patients; 
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• Possible referral bias to a tertiary specialist clinic. Caucasian patients tend 
to go to private hospitals or medical facilities, while rural black African 
patients attend clinics closer to home. Therefore, the majority of patients 
seen in our clinics were individuals from the mixed ancestry popUlation 
group. 
For these reasons, the control cohort used in this study could not be ethnically 
matched to the study cohort at the time of reporting these results. The result was that 
caucasian and black African patients were underrepresented in our control cohort, 
when compared to the study cohort. These limitations may be corrected by enlarging 
the control cohort for future studies. Where appropriate, during the statistical 
analyses, ethnic differences were taken into account when drawing conclusions. 
While mindful of the limitations, the current HBV cohort had major benefits in that it 
provided cases that were clinically and immunologically free of autoimmune disease. 
HBV infection is a non-immune disease that is endemic in southern Africa. The 
development of disease appears to be dependent on random clinical exposure to 
HBV rather than immunogenetics. HBV infection is entirely preventable with 
immunisations in all ethnic groups. 
6.2 DNA Isolation and Amplification (peR) 
Blood samples were collected from patients and the DNA isolated over a period of 2 
years. All DNA samples were stored at -80°C. The DNA yield of 4 of these samples 
was very low, leading to problems with the PCRs. No fresh blood samples could be 
obtained from these patients. PCR products for these smnples were obtained for 
some, but not all the amplicons of interest. 
6.3 RE Analysis 
The RE analyses designed for the purpose of this study (see section 4.3.1; page 35) 
proved successful in genotyping patient and control DNA for the -318 crr, +49 AlG 
and CT60 G/A CTLA4 polymorphisms. 
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No significant differences were observed for genotypic or allele frequencies of the 
-318 crr promoter polymorphism between the study and control cohorts. Power 
calculations (not shown) on our data indicated that, if our study cohort consisted of 
200 individuals and our control cohort of 100 individuals, the observed genotypic 
frequencies at this locus would become significant (p = 0.0435) at the 5% confidence 
interval. As mentioned in section 1.3.2.2, page 15, published data by Fan et al 
(2004) showed a significant association of the -318 C allele with AIH in Chinese 
patients. No associations have been found for the -318 CIT polymorphism with 
either autoimmune thyroid disease or SLE in European caucasian, Chinese, Japanese, 
Spanish or Korean patients (Heward et al 1998; Ahmed et al 2001; Aguilar et al 
2003; Hudson et al2002). 
Only one of our patients and none of the controls were homozygous for the -318 T 
allele. Interestingly, the one patient that did have this genotype had very severe 
disease. This particular patient was a female caucasian, aged 20 years. She had high 
INR (5.2) and low ALB levels (27 giL) and was deeply jaundiced at presentation. 
Submassive necrosis was found on the liver biopsy with features of bile duct injury 
suggestive of an overlap syndrome. This patient also had a strong family history of 
atopic eczema and other autoimmune diseases including psoriasis, IDDM and RA. 
No conclusions can yet be made on the basis of this. However, it would be 
interesting to investigate the possibility that the -318 T allele relates to severity of 
disease. Published data from two previous studies on the -318 crr polymorphism 
indicated an association with Wegener's granulomatosis in Swedish patients, and a 
possible role for the C to T change in the regulation of CTLA4 expression (Giscombe 
et a12002; Wang et a12002). Initial work by Giscombe et al (2002) showed that the 
-318 C allele was significantly decreased and the -318 crr genotype significantly 
increased in patients with Wegener's granulomatosis compared with controls. No 
homozygous individuals in either Wegener's granulomatosis patients or healthy 
controls could be demonstrated. In a follow-up study, Wang et al showed an 
association of the -318 T allele with higher C1LA4 promoter activity than the -318 C 
allele. The group therefore proposed that the -318 T allele is protective against 
autoimmune reactions in Swedish patients (Wang et al2002). Our [mdings, although 
based on the data from only one patient, suggests that the -318 T allele, rather than 
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being protective, is associated with autoimmune disease and the presence the -318 
Trr genotype results in a clinical phenotype of a more severe form of disease. In 
order to clarify the role of the -318 T allele in South African AIH patients, the effect 
of this polymorphism on promoter activity and expression of the CTLA4 protein 
needs to be investigated. In order to do this, more patients and controls with the -318 
TIT genotype are required. 
The frequency of the CTLA4 +49 GIG genotype appeared slightly lower in the study 
cohort when compared with the controls (see figure 5.7; page 50). However, the 
differences observed between our study cohort and controls were not statistically 
significant Power calculations (not shown) indicated that, if our study cohort 
consisted of300 individuals and our control cohort of200 individuals, the observed 
genotypic frequencies at the +49 AlG locus would become significant (p = 0.0238) at 
the 5% confidence interval. Therefore, a larger study would increase the statistical 
power of our data. 
If the observed decrease in the +49 GIG genotype frequency of our study cohort was 
found to be significant in a larger study, this would indicate a possible protective 
effect for the +49 GIG genotype. This would be in agreement with published data 
from Ojilali-Saiah et al (2001). In previous pilot studies we have shown a lack of 
association between the +49 AlG polymorphism and AIH or SLE (Hairwadzi et al 
2002). This finding, as well as the possibility of an observed decrease in the 
frequency of the +49 GIG genotype becoming significant with increased power for 
the study, contrasts with other published data. Indeed, previous studies have shown 
an association of the +49 GIG genotype with AIH in northern European and Chinese 
patients, 100M in Iranians and SLE in Japanese patients (Agarwal et al2000; Fan et 
a12004; Mojtahedi et a12005; Ahmed et aI2001). No association was found 
between the +49 AlG polymorphism and SLE in Spanish and Korean patients 
(Aguilar et al2003; Hudson et al2002). 
Similarly, the frequency of the CT60 AI A genotype appeared slightly higher in our 
study cohort, when compared to the controls (see figure 5.10; page 53). Once again 
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this observed difference was not found to be statistically significant. A larger study 
and control cohort is needed in order to accept or reject this finding. Power 
calculations (not shown) showed that for a study cohort of200 individuals and a 
control cohort of 100 individuals, the same observed frequency would become 
significant at the 5% confidence interval. Veda et al (2003) described the CT60 G 
allele, and subsequently the CT60 GIG genotype, as disease-predisposing in 
autoimmune hypothyroidism and Graves' disease, while the effect was much weaker 
in 100M. Furthermore, a study by Van BeIzen et al (2004) showed an equivocal 
significant increase (p = 0.048) in the CT60 G allele in Dutch coeliac disease 
patients. However, no significant difference was found by this group when they 
compared the genotypic frequencies of patients with that of controls. 
Our study demonstrated a highly significant difference amongst ethnic groups at the 
CTLA4 CT60 locus (p = 0.00056). The observed frequencies showed a clear 
overrepresentation of the CTLA 4 CT60 GIG genotype in our black African patients, 
while the CT60 N A genotype was completely absent from this group. Asian 
patients had the highest frequency of N A genotype and the lowest frequency of GIG 
genotype. Similarly, the differences in allelic frequencies at this locus were highly 
significant (see section 5.4; page 53 and figure 5.11; page 54). This should be 
further investigated with larger numbers of individuals from black African and Asian 
patient groups, and the results would have to be compared to ethnically matched 
control cohorts with sufficient statistical power. 
6.4 Mutation Screening 
No new polymorphisms or mutations were identified within our family-based cohort. 
As mentioned in section 6.1; page 65, these patients were chosen on the basis of the 
availability of affected and unaffected family members with autoimmune disease for 
follow-up studies. Therefore, the number of patients recruited for this section of the 
study was small and a bigger cohort is required to confirm I refute these findings. 
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6.5 ELISA 
There is conflicting data on the nonnal range for sCTLA4 levels in human serum. 
Published data by Purohit et al (2005) and Wong et al (2005) found median 
concentrations of 1.69 nglml (range 0.0-11.5 ng/ml) and 1.61 nglml (range 1.32-1.85 
ng/ml), respectively, for nonnal controls, while Magistrelli et a1 (1999) reported a 
median concentration of36 nglml (range 3-90 nglml). Oaks and Hallet (2000) found 
the concentration of sCTLA4 in their healthy individuals to be "virtually 
undetectable". We accepted the manufacturer's analyses that there are no detectable 
levels of sCTLA4 in healthy patients. 
To our knowledge, no previous studies have investigated the concentration of 
sCTLA4 patients with AlH. The serum sCTLA4 concentrations of our AIH patients 
were below 1.5 nglml regardless of the stage of disease activity. However, further 
studies are needed to investigate the nonnal range of sCTLA4 in healthy South 
African individuals and those with other autoimmune disease, in order to confInn 
that our patients' results do not differ significantly from nonnal. Available funding 
for this project and the high cost of the sCTLA4 kits prohibited us from establishing 
a local control range, and we deemed it acceptable to follow the manufacturers 
findings. Our focus was on whether or not there is any detectable, significant 
correlation in sCTLA4 concentrations with disease severity. 
The serum sCTLA4 concentrations of our AIH patients were very low to 
undetectable in all cases. Furthennore, there was no significant difference between 
serum sCTLA4 concentrations from serum samples taken at presentation of active 
AIH, and those taken after three months of immunosuppressive treatment and 
achievement of disease control. This suggests that the concentration of sCTLA4 is 
not associated with disease activity in South African patients with AlH. However, a 
more sensitive test, when available, might be valuable to conflnn our results. 
Further studies investigating the differences of sCTLA4 concentrations at these two 
time points should be perfonned in patients with other autoimmune conditions, such 
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as SLE and autoimmune thyroid disease. Published data in these diseases indicate 
higher concentrations of the soluble fonn of the protein at presentation with disease 
(see section 1.3.2.3; page 17). Such studies may clarify a role for sCTLA4 in various 
stages of autoimmune disease and allow us to further interpret our AIR results. 
6.6 Patient Demographics 
Black African patients from our study cohort were, on average, 12.78 years younger 
than caucasians at presentation with AIR. This is in agreement with preliminary 
studies described in section 2.4; page 27. This indicates that black African patients 
in South Africa present with disease at a younger age than caucasian patients. The 
reason for this is still unclear but could be due to a number offactors. For example, 
there could be further clinical factors, such as exposure to pathogens, or genetic or 
cultural factors, such as environment and living conditions. Further studies would 
need to investigate all these possibilities, to fully elucidate the reasons for our 
findings. 
Female patients across all ethnic groups in our study cohort were, on average, 13.47 
years older at presentation than their male counterparts. To our knowledge, no other 
studies have shown this before. Once again, the reasons for this need to be 
investigated in future studies. Possible detenninants for this could include honnonal 
or genetic differences and/or cultural nonns. Thus, studies correlating liver 
autoantibody profiles, HLA profiles and other factors affecting immune modulation 
with sex could be infonnative. 
6.7 Disease Severity Markers 
ALT, INR and ALB values were used as standard markers of disease severity in our 
study cohort. These indices are widely used as markers of liver function. In order to 
determine whether the CTLA4 polymorphisms, -318 CIT, +49 NG and CT60 G/A, 
played a significant role in disease severity, we investigated any possible association 
between these polymorphisms and these indices. The disease severity indices of the 
AIR patients were not significantly associated with any of the genotypes or alleles of 
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the polymorphisms investigated. This was true with or without adjusting for age 
and/or race. 
Kruskal-Wallis test p-values indicated a significant difference in INR and ALB 
medians amongst ethnic groups. The biggest difference was observed between the 
black African and caucasian groups. The median ALB level in black Africans was 
lower by 7.5 gIL, compared to caucasians and the median INR was 0.55 higher in 
black Africans compared with caucasians. Since ALB and INR are both direct 
measures of liver function, these differences indicate that black African patients tend 
to have more severe disease than their caucasian counterparts. No significant 
difference was found for the AL T values amongst ethnic groups. High AL T 
concentrations only indicate the presence of liver injury and in no way correlates 
with disease severity. No significant difference was found in the median severity 
markers between sexes. 
Previous studies have suggested that older patients with Am tend to have more 
severe disease, histologically, at presentation compared to their younger counterparts 
(Newton et al 1997). It is not clear what the reasons for this are. It is also not clear 
whether such disease at an older age is de novo Am or a clinical presentation of 
previously ongoing, asymptomatic Am. Our study showed that INR correlated 
negatively with age, while ALB correlated positively with age. The ALT showed no 
significant correlation with age. In other words, INR appears lower, and ALB higher 
with advanced age of first presentation of Am. This finding suggests that older 
South African patients have biochemically less severe disease at first diagnosis 
compared to their younger counterparts. 
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Chapter 7 
Conclusions and Future Work 
This study is the first to investigate all the known CTIA4 gene polymorphisms, with 
the exception of the (AT)n micro satellite repeat in the 3 I UTR, in Am, and attempt 
to correlate this with ethnicity, sex, disease activity and severity. It is also the first to 
investigate sCTLA4 protein in Am during active (at presentation) and inactive 
disease (after 3 months of treatment). 
7.1 Conclusions and Future studies 
• No new polymorphisms or mutations were identified in those South African 
patients with Am in our cohort. However, new polymorphisms or mutations 
may be revealed in Am patients as yet not studied. 
• The CTIA4 -318 crr promoter polymorphism, the +49 AlG polymorphism in 
exon 1, and the CT60 G/ A polymorphism in the UTR 3 I of CTIA4 were not 
significantly associated with disease in South African Am patients. However, 
a larger cohort may be needed in order to verify this. 
• At presentation, black African patients from our Am cohort tend to have more 
severe disease at a younger age than their caucasian counterparts. Although 
the reason for this remains unclear a significant difference in the frequency of 
the CT60 G/G genotype amongst ethnic groups was observed. Black African 
Am patients in this study showed a higher frequency of this genotype 
compared to other ethnic groups, while the CT60 AI A genotype was 
completely absent. The possibility that this could contribute to disease 
susceptibility or severity in black African patients needs to be further 
investigated. 
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• South African female Am patients tend to be older at presentation than their 
male counterparts. Once again, the reasons for this need to be investigated. 
• The significance of the rarity of the -318 Tff genotype needs to be 
investigated. Our study suggests the possibility that the T allele associates with 
acute severe presentation of Am in young patients. However, as this 
observation is based on data from a single patient, it is unwise to draw any 
conclusion at this stage. Thus, whether or not the -318 T allele relates to 
severity of disease and the possible reasons for the rarity of the -318 Tff 
genotype in our population are intriguing questions requiring further 
investigation. 
To answer such questions a follow-up study prospectively investigating 
patients who present with acute, severe disease should be performed. To date 
such patients have been difficult to study as they often die before they can be 
legitimately entered into such a study. 
• sCTLA4 concentration did not correlate with disease activity in AIH in South 
African patients. However, measurement of sCTLA4 in larger numbers of 
Am patients, other autoimmune conditions and in a local, control population 
will confirm this and/or allow further interpretation. 
• The influence of CTIA4 polymorphisms on disease susceptibility and severity, 
if at all relevant, must be small, or as yet, not clear. Polymorphisms may work 
in a "facilitating" manner along with other genetic and/or external factors. 
Possibly a larger study cohort, which combines patients and data from various 
centres around the world, may shed light on a role for CTIA4 in Am. 
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Appendix A 


















Clinical description of the General AIH Study Cohort. Where possible, 
patients' sex, ethnicity and age are indicated together with their liver 
biochemistry indexes: alanine aminotransferase (ALT), international 
normalised ratio (INR) and ALB (albumin). The indexes ALT, INR and 
ALB are important measures of liver inflammation and are therefore 
important in assessing the severity of disease (see section 2.2.1; page 22). 
Sex Ethnicity ALT INR ALB Age 
Male Caucasian 83 1.4 49 30 
Male Caucasian 39 2.1 33 20 
Male Caucasian 1872 33 48 
Female Asian 180 22 37 
Female Black African 20 35 72 
Female Caucasian 45 
Female Mixed Ancestry 66 1.1 41 47 
Male Caucasian 240 1.1 35 24 
Male Asian 87 38 26 
Female Mixed Ancestry 107 2.8 16 14 
Male Black African 1022 1.8 30 33 
Female Black African 118 0.9 27 62 
Male Black African 17 
Female Black African 339 1.3 35 36 
Male Caucasian 25 
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Patient Code Sex Ethnicity ALT INR ALB Age 
317 Male Black African 92 1.9 14 24 
318 Female Caucasian 55 1.3 39 37 
320 Female Black African 55 4.6 31 20 
324 Female Mixed Ancestry 17 
326 Female Asian 472 4.6 18 45 
329 Female Caucasian 79 1.2 28 52 
334 Male Asian 167 2 41 17 
335 Female Mixed Ancestry 635 4.1 20 27 
336 Male Black African 225 1.6 27 12 
347* Female Mixed Ancestry 626 1.4 36 40 
350 Male Asian 230 1.5 33 44 
351 Female Mixed Ancestry 337 22 52 
361* Female Mixed Ancestry 400 23 30 
362 Female Caucasian 118 1.1 44 40 
382 Female Mixed Ancestry 115 0.9 45 36 
383 Male Caucasian 151 0.9 39 50 
389 Female Mixed Ancestry 431 0.9 44 58 
393* Male Black African 330 1.6 31 17 
402 Female Caucasian 1522 41 16 
414 Male Caucasian 172 0.9 41 46 
415 Female Mixed Ancestry 2167 1.4 32 34 
416* Female Asian 98 0.9 40 34 
424 Female Black African 219 1.6 35 24 
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Patient Code Sex Ethnicity ALT INR ALB Age 
450 Female Asian 945 1.3 28 49 
455* Female Caucasian 71 5.2 27 20 
465 Female Mixed Ancestry 419 1.8 31 47 
503* Female Mixed Ancestry 379 1.1 34 46 
504* Female Mixed Ancestry 719 2.4 14 29 
509 Male Mixed Ancestry 80 1.3 34 46 
520 Female Caucasian 47 44 53 
534 Female Caucasian 664 37 41 
539 Female Caucasian 184 35 66 
614* Female Asian 214 0.8 43 20 
641 Male Caucasian 74 20 4 
649 Female Black African 812 1.1 36 37 
655 Male Black African 83 1.8 17 19 
669 Female B lack African 30 1.5 17 16 
695* Female Mixed Ancestry 40 1.3 36 50 
699 Female Mixed Ancestry 101 1.9 33 14 
707 Female Mixed Ancestry 418 22 41 
720 Female Caucasian 12 39 70 
726* Female Mixed Ancestry 457 40 55 
730 Female Mixed Ancestry 162 35 6 
732 Female Black African 213 39 28 
733 Female Asian 902 1.5 41 65 
739 Female Asian 1920 3.1 28 35 
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Patient Code Sex Ethnicity ALT INR ALB Age 
741 Female Caucasian 405 1.4 23 61 
875 Female Black African 400 1.8 32 34 
876 Female Mixed Ancestry 213 1.2 45 32 
877 Female Black African 132 1.71 17 30 
878 Female Mixed Ancestry 27 1.9 50 57 
880 Female Asian 248 1.8 13 45 
881 Female Caucasian 808 40 34 
884 Female Mixed Ancestry 1216 1.2 31 49 
888 Female Asian 47 1 48 51 
890 Male Mixed Ancestry 1300 1.3 36 31 
901 Female Mixed Ancestry 1049 15 39 82 
902 . Female Caucasian 539 0.8 36 58 
904 Female Caucasian 230 45 47 
905 Female Mixed Ancestry 18 1.2 42 64 
906 Female Black African 437 1.2 39 54 
908 Female Caucasian 1750 1.3 45 46 
909 Female Mixed Ancestry 716 3.3 37 54 
917 Female Caucasian 1.5 0.8 31 61 
921 Female Black African 144 1.4 30 38 
926 Female Caucasian 184 38 45 
932 Male Mixed Ancestry 125 1.6 12 12 
933 Male Mixed Ancestry 980 2.2 21 24 
935 Male Mixed Ancestry 1008 1.5 44 29 
89 
Patient Code Sex Ethoicity ALT INR ALB Age 
938 Female Caucasian 91 39 56 
942 Female Black African 64 1.4 16 7 
944 Female Caucasian 65 
946 Female Black African 115 1.4 39 23 
948 Male Asian 215 1.2 42 20 
949 Female Mixed Ancestry 1428 1.2 29 42 
951 Female Caucasian 105 32 64 
952 Female Asian 95 2.3 15 48 
960 Female Black African 86 1.2 38 52 
961 Female Mixed Ancestry 80 1.6 28 70 
964 Female Caucasian 213 1.4 38 55 
966 Female Black African 199 1.7 23 34 
967 Female Caucasian 1254 1.5 39 30 
968 Female Asian 84 35 56 
970 Female Mixed Ancestry 772 1.8 35 25 
974* Female Mixed Ancestry 1729 2.3 37 32 
984 Female Mixed Ancestry 38 1.6 41 16 
987 Female Caucasian 303 0.8 41 43 
994 Female Black African 49 2.1 13 14 
997 Female Mixed Ancestry 85 3.9 45 56 
999 Female Mixed Ancestry 990 1.8 27 6 
1001 Female Mixed Ancestry 480 1..2 36 49 
1002 Female Caucasian 87 1.23 28 65 
90 
Patient Code Sex Ethnicity ALT INR ALB Age 
1004 Female Mixed Ancestry 242 21 16 
1005 Female Mixed Ancestry 1975 2 42 52 
1008 Female Mixed Ancestry 90 0.7 43 45 
1009 Female Black African 346 38 36 
1010 Male Mixed Ancestry 103 1.3 37 13 
1016 Female Caucasian 280 36 27 
1017 Male Mixed Ancestry 415 39 52 
1020 Female Mixed Ancestry 1248 2.1 27 22 
1023 Female Mixed Ancestry 365 1.2 32 33 
1024 Female Black African 153 2.28 24 34 
1025 Female Caucasian 278 1.2 36 44 
* Patients that were included in the family cohort 
Normal ranges of liver biochemistry indexes: ALT <40; INR <1.2; ALB 35-40. 
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AppendixB 
Isolation of Genomic DNA from Whole Blood 
B.1 Materials 
B.1.1 Equipment 
• Sterile 15 ml centrifuge tubes (Axygen Scientific, Union City, USA) 
• Super-Mixer 220V Vortex (Lab-Line Instruments, Melrose Park, USA) 
• Techne Dri-Block DB· 2D Heating Block (Techne, Cambridge, UK) 
• Jouan KR4 22 High Capacity Refrigerated Centrifuge (Jouan, Winchester, 
USA) 
• Gilson Pipetman PlOOO (Gilson Medical Electronics, Villiers-Ie-Bel, France) 
• Sterile Pipette tips (Whitehead Scientific, Cape Town, South Africa) 
• 5 and 10 ml Sterilin Sterile Disposable Plastic Pipettes (Bibby Sterilin, 
Staffordshire, UK) 
B.1.2 Reagents 
• Wizard Genomic DNA Purification Kit (Promega, Madison, USA) 
• Reagents provided by the manufacturer (Promega, Madison, USA) 
Cell lysis solution 
Nuclei lysis solution 
- Protein precipitation solution 
- DNA rehydration solution 
- RNase solution 
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• Isopropanol, room temperature (Riedel-de Haen, Sigma-Aldrich GmbH, 
Steinheim, Germany) 
• 70% Ethanol, room temperature (Sigma-Aldrich GmbH, Steinheim, Germany) 
B.2 Methods 
• Add 7.5 ml of cell lysis solution to a sterile 15 ml centrifuge tube. 
• Gently invert the tube of blood until thoroughly mixed. Transfer 2.5 ml of 
blood to the tube containing the cell lysis solution. Invert the tube 5-6 times to 
mix. 
• Incubate the mixture for 10 min at room temperature (invert 2-3 times once 
during the incubation) to lyse the red blood cells. Centrifuge at 2,000 xG for 
10 min at room temperature. 
• Remove and discard as much supernatant as possible without disturbing the 
visible white pellet. Approximately 50-100 III of residual liquid will remain in 
the 15 ml tube. If blood sample has been frozen, repeat the above four steps 
until pellet is white. There may be some loss of DNA from frozen samples. 
• Vortex the tube vigorously until the white blood cells are resuspended (10-15 
s). 
• Add nuclei lysis solution (2.5 ml) to the tube containing the resuspended cells. 
Pipet the solution 5-6 times to lyse the white blood cells. The solution should 
become very viscous. If clumps of cells are visible after mixing, incubate the 
solution at 37°C until the clumps are disrupted. If the clumps are still visible 
after 1 h, add additional nuclei lysis solution (825 Ill) and repeat the incubation. 
• Optional: Add Rnase solution (825 Ill) to nuclear lysate and mix the sample by 
inverting the tube 2-5 times. Incubate the mixture at 37°C for 15 min, and then 
cool to room temperature. 
• Add protein precipitation solution (825 Ill) to the nuclear lysate and vortex 
vigorously for 10-20 s. Small protein clumps may be visible after vortexing. 
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• Centrifuge at 2,000 xG for 10 min at room temperature. A dark brown protein 
pellet should be visible. 
• Transfer the supernatant to a 15 ml centrifuge tube containing 2.5 ml room 
temperature isopropanol. 
• Gently mix the solution by inversion until the white thread-like strands of DNA 
form a visible mass. 
• Centrifuge at 2,000 xG for 1 min at room temperature. The DNA will be 
visible as a small white pellet. 
• Decant the supernatant and add one sample volume of room terperature 70% 
ethanol to the DNA. Gently invert the tube several times to wash the DNA 
pellet and the sides of the microcentrifuge tube. Centrifuge as above. 
• Carefully aspirate the ethanol using either a pipette. The DNA pellet is very 
loose at this point and care must be taken to avoid aspirating the pellet into the 
pipette. Invert the tube on clean absorbent paper and air-dry the pellet for 10-
15 min. 
• Add DNA rehydration solution (200 Ill) to the tube and rehydrate the DNA by 
incubating at 65°C for 1 h. Periodically mix the solution by gently tapping the 
tube. Further rehydrate the DNA by incubating the solution overnight at room 
temperature. 
• Store the DNA at 4°C. 
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Appendix C 
Annotated Genomic Sequence for CTLA4 
Table C.I Annotated genomic sequence of the CTLA4 gene. Capital letters indicate 
trcmslated regions of the gene. Primers are indicated with boxes around the text. 
Positions of pubJished polymOIphisms are indicated with a 1\ or 1\1\ and explaino:l in 
blue directly underneath the indicator. S1art and stop codons are red and in bol •. 
Where parts of1he sequence are ~ they are replaced with ( ... ). 
1 ccctttctga cttccacagg ctgaaccact ggcttctgct cctctacata atacttcaat 
61 tccagcattg atctcactct atcatgatca tgggtttagc tgtctgtccc tgccactgct 
121 gtgtgttcct cttgagggca ggaacatttg tttttcactt tttaaaaaac ctctgttgcc 
181 cagtctggca ttaggaagtg cccattaggt tgttattgct tgttggcgct tgagctgggg 
961 atttaatctt cacttttgaa ttttctgctt gaaaaatttg tattagaaaa aaaagtctat 
1021 ccttttatgg acggctctaa tctcttgaat catttgggtt ggcttttctt tggaccttct 
1081 tcaactctgt tttgtctctg ttgagttaag gcttttaaga acacctgaat tctttccttc 
1141 tgcaaaacca gaggcagctt cttttccgcc tattttcagt ttatttcttg tgattttagt 
1201 ttttttctct taaccaaatg ctaaatggat ttaggagaaa taaacttatt tgtaaagctg 
1261 tcaa~~acc attagaagga t22t2~tca cagatagaat acagttttta ttaatgatgc 
C!'LA4I'promA 
1321 ctagacaaat cctgccatta gcccaagggc tcagaaagtt agcagcctag tagttttg~a 
1381 gatgtcaatg aaatgaattg gactggatgg ttaaggatgc ccagaagatt gaataaaatt 
1441 gggatttagg aggacccttg tactccagga aattctccaa gtctccactt agttatccc=.g 
1501 atcct~caaag tgaacatgaa gcttcagttt caaattgaat acattttcca tccatggc=.tt 
CIT cr014435 (-318C/T) 
1561 ggcttgtttt gttcaJgttga 2tgctt2a22 tt~~tttc gacgtaacag ctaaac~ 
c.r.r.a.4I'1 
1621 fi2cttccttt ctcgta3aac caaaacaaaa aggctttcta ttcaagtg 
c.rLAGpromA 
bOD 1 cc ttctgtgtCJt 
1681 gcacatgtgt aatacatatc tgggatcaaa gctatctata taaagtcctt gattctgtCJt 
1741 gggttcaaac acatttcaaa gcttcaggat cctgaaaggt tttgctctac ttcctgaaCJa 
1801 cctgaacacc gctcccataa agccA'fGGCT TGCCTTGGAT TTCAGCGGCA CAAGGCTCAG 
1861 CTGAACCTGG CT~GCCAGGAC CTGGCCCTGC ACTCTCCTGT TTTTTCTTCT CTTCATCC~~CT 
95 
G/A rs231775 (+49A/G) 
G/C rs16840275 
1921 GTCTTCTGCA AAG 
Intron 1 gtgagtg agacttttgg agcatgaaga tggaggaggt gtttctccta 
1981 cctgggtttc atttgtttlca 2cagtcaa"g2 gcagt2att§ atagcaaagc cagaagt~aa 
a/g rs231776 C!"liA4R.1 
2041 aggtaaaact ccaatctggc ttggctggct ctgtattcca gggccagcag ggagcagttg 
2101 ggcggcagca aataaggcaa agagatagct cagaacagag cgccaggtat ttagtagg<;:g 
2161 cttcatgaat gcatgtgagt tggtttagta gagagacaca ggcaatttca gacccttcta 
4201 tgtttgtcat atcagtgttc ttcctgccac aaccatcttg aagaatctat ttctcagtaa 
4261 gaaaatatct ttatggagag tagctggaaa acagttgaga gatggagggg aggctggg<;:g 
4321 tgtggagagg ggaaggggta agtgatagat tcgttgaagg ggggagaaaa ggccgtg~ 
4381 Etgaagctag aaggca91aag ggcttgcctg ggcttggcca tgaaggagca tgagttca-::t 
c.l'.r.&41'2 
4441 gagttccctt tggcttttcc atgctag 
bOD 2 CAA TGCACGTGGC CCAGCCTGCT GTGGTACTGG 
4501 CCAGCAGCCG AGGCATCGCC AGCTTTGTGT GTGAGTATGC ATCTCCAGGC AAAGCCAC'IG 
4561 AGGTCCGGGT GACAGTGCTT CGGCAGGCTG ACAGCCAGGT GACTGAAGTC TGTGCGG~A 
4621 CCTACATGA"T GGGGAATGAG TTGACCTTCC TAGATGATTC CATCTGCACG GGCACCTCCA 
T/C rsl065442 
4681 GTGGAAATCA AGTGAACCTC ACTATCCAAG GACTGAGGGC CATGGACACG GGACTCTACA 
4741 TCTGCAAGGT GGAGCTCATG TACCCACCGC CATACTACCT GGGCATAGGC AACGGAACCC 
4801 AGATTTATGT AATTG 
Intron 2 gtgag caaagccatt tcactgagtt gacacctgtt gcattgca£'t 
4861 cttctatgca caaaaacagt tttgttcctt aatttcagga ggtttacttt taggactgtg 
4921 gacattctct ttaagaJittc t2taccacat ggtag9fttg cttattgtgg gtggcaac=t 
c.u.&4R2 
4981 taatagcatt ctgactgtaa aataaaatga tttggggaag ttggggctct cgctctggag 
5041 tgctaaccat catgacgttt gatctgtact tttgatatga tatgatgctc ctggggaagt 
5101 agtcccaaat agccaaacct attggtgggc tacccatgca atttaggggt ggacctcaag 
5161 ~cct2gaagc tctaat2tc~ ttttttcacc aatgttgggg agtagagccc tagagttt~a 
c.l'LA.4I'3 
5221 aactgtctca gggaggctct gctttgtttt ctgttgcag 
bon 3 A TCCAGAACCG TGCCCAGA~T 
5281 CTGACTTCCT CCTCTGGATC CTTGCAGCAG TTAGTTCGGG GTTGTTTTTT TATAGCTT~C 
5341 TCCTCACAGC TGTTTCTTTG AGCAAAATG 
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J:ntron 3 9 tgagtgtggt gctgatggtg caccatgtct 
5401 gatggggata cctttagtgg tatcaactgg ccaaaagatg atgttgagtt tagtgttctt 
5461 gagatgagat gaggcaataa atgaagagga aggacagtgg taaaga~cgc actagaacc~ 
5521 ~aggca!ltgg catttgaggt ttcagaatga ctaatatttt agatgaattt gtttgacatt 
C1'LA4R3 
5581 gaatgttcat gtgcttctga gcagggtttc aatttgagta accgttgcaa taacatgggg 
5641 cagctqtttt gctctttgtc ttcatgacaa ctgtacttaa gctaacagcc ctgaaacatg 
5701 agattaggct gggcagaatg ctgctagaga ggaccacttg gatggtcttt attctccttc 
6301 caattatcat aggctttctg ggtqttcttt ctgaagcttt ctcaaagtct ctttctccta 
6361 tcttccattc aaggcaaatg attgccattt aacatcaaaa tcacagttat ttatctaaaa 
6421 taaattttaa tagctgaatc aagaaaatct cctgaggttt ataattctgt atgctgtga"a 
a/g rs11571318 
6481 cattcatttt taE;ccagcta gggacccaat at(Jftgttgag ttctattatg gttagaagtg 
CL'1A4I'4a 
6541 gcttccgtat tcctcagtag taattactgt ttctttttqt gtttgacag 
hon 4 C TAAAGl\AAA.G 
6601 AAGCCCTCTT ACAACAGGGG TCTATGTGAA AATGCCCCCA ACAGAGCCAG AATGTGl\AAA. 
6661 GCAATTTCAG CCTTATTTTA TTCCCATCAA TTGAgaaacc attatgaaga agagagtcca 
6721 tatttcaatt tccaagagct gaggcaattc taactttttt gctatccagc tatttttatt 
6781 tgtttgtgca tttgggggga attcatctct ctttaatata aagttggatg cggaacccaa 
6841 attacgtgta ctacaattta aagcaaagga gtagaaagac agagctggga tgtttctgt€) 
6901 ~catca2ctc cactttca~ gaaagcatca cttgggatta atatggggat gcagcattat 
C!'1A4R4a 
6961 gatgtgggtc aaggaattaa gttagggaat ggcacagccc aaagaaggaa aaggcaggga 
7021 gcgagggaga agactatatt gtacacacct tatatttacg tatgagac"gt ttatagccga 
G/A rs13384548 
7081 aatgatcttt tcaagttaaa ttttatgcct tttatttctt aaacaaatgt atgattacat 
7141 caaggcttca aaaatactca catggctatg ttttagccag tgatgctaaa ggttgtattg 
7201 catatataca tatatatata tatatatata tatatatata ttttaatttg atagtattgt 
7261 gcatagagcc acgtatgttt ttgtgtattt gttaatggtt tgaatataaa cactatatgg 
7321 cagtgtcttt ccaccttggg tcccagggaa qttttgtgga ggagctcagg acactaatac 
7381 accaggtaga acacaaggtc atttgctaac tagcttggaa actggatgag gtcatagcag 
7441 tgcttgattg cgtggaattg tgctgagttg qtgttgacat gtgctttggg gcttttacac 
7501 cagttccttt caatggtttg caaggaagcc acagctggtg gtatctgagt tgacttgaca 
7561 gaacactgtc ttgaagacaa tggcttactc caggagaccc acaggtatga ccttctagga 
7621 agctccagtt cgatgggccc aattcttaca aacatgtggt taatgccatg gacagaagaa 
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7681 ggcagcaggt ggcagaatgg ggtgcatgaa ggtttctgaa aattaacact gcttgtgttt 
7741 ttaactcaat attttccatg aaaatgcaac aacatgtata atatttttaa ttaaataaaa 
7801 atctgtggtg gtcgtttt 
3'UT,R Icc ggagttgtct ttatcatc~ tgcatttgaa tattgtgtt~t 
tic rs231721 crLA4r3UT.R 
7861 aaatttttga ttgattcatt cagtatctgg tggagtctcc aatattagaa atactggaaa 
7921 caaactgaaa aaccacaaaa ggacaaataa tgcttcatga gtcagctttg caccagccat 
7981 tacctgcaag tcattcttgg aaggtatcca tcctctttcc ttttgatttc ttcaccacta 
8041 tttgggatat aac~gtgggtt aacacagaca ta~~gcagtcct ttataaatca 
attlggcatgCJ 
g/a rs3087243 (CT60) 
g/a rs1l571319 
8101 fugtttaacac agg~cttca cctccccttt cttaccgcct gctttctcag ctcaacta=c 
CT1Jl4R3tJ'm 
8161 acaggcatta cagttgtcat ggcaacccca atgttggcaa ccacgtccct tgcagccatt 
8221 ttgatctgcc ttcctgaaat atagagcttt tccctgtggc ttccaaatga actatttt~c 
8281 aaatgtgggg aaaacacaca cctgtggtcc tatgttgcta tcagctggca cacctaggcc 
8341 tggcacacta agccctctgt gattcttgct taaccaatgt atagtctcag cacatttg~t 
8401 ttccacttaa ggtttcctat ttttgacctc cacatcctgt tattgtcttt tgcagtgatt 
8461 ctcagtgtgg tcagggacca cctgtaactg aatccactgg gtcacttact aaaaacacca 
8521 attcacactt attcccagat gcgttgaatc agaatctttg agtggtgggg ccaggagttt 
8581 gtatttccaa aaatcttccc agtgcttctt atacccatca agttttgaga atcactgctt 
8641 aggcaactct gtctgtgtct cttcctctgt ctctccccct tgctcattct cttgcttgct 
8701 cttgctctct ttctctcttt cttgccccag caagtgctaa caaacacaca agacagcaca 
8761 tagtaagcat ttcaaaaggg gttgttaaat aaaaacgaat aggtctttca aagtaaggta 
8821 atgattatta cctagaatga gctccttttc tgtggaagac tgtgcttctt gctctctaqg 
8881 cctttggatg gtagccatga agaaaaacac caatcgggag cctcagtgga tagtatatca 
8941 tttccactcc tctaaacgtc tttagagaga ttactctttt tcatagttga tgggcagatc 
9001 tgagtgacag agagtgcctt acacaagtga tgccctccag gtacctttca gacaccctta 
9061 gataatggac tactttatat aagcttaata tttcctctgc tattgcctaa aattctacca 
9121 tttgttgttc actgagataa gacttgccct cttcattcag tctcaatctt ataaaaataa 
9181 aatacccttt agctcaaaaa agcttcccct atggcagaag aattgtacaa gaaagactat 
9241 gacccggggt tccgctgaaa ggggagaaag caaatatgag ggtaagggag tgcatctgqg 




D.l Primer Criteria 
• Primer lengths of 18 to 22 bp were chosen to ensure specificity. Shorter 
primers generally tend to bind more non-specifically to the genome. 
• Amplicon sizes of no more than 600 bp were chosen, to ensure compatability 
with WAVE. 
• Melting temperatures (Tm) of 55 to 65°C were favoured. 
• The Tm difference between primers of a pair was chosen to be ideally no more 
than 2°C (maximum 5°C). 
• . GC contents of 45 to 60% were favoured. 
• Primer dimer formation due to complementarity between primers was avoided. 
• The possibility of a primer folding back on itself and creating a hairpin loop 
due to self-complementarity was examined, and where possible avoided. If a 
loop forms at the 3 I end of a primer, the 3 I OH group is inaccessible to the 
Taq Polymerase for elongation of the strand. However, if this occurs at the 5 I 
end, the primer can still be functional, but will in effect be shorter, resulting in 
possible non-specificity. 
• Sequences containing three or more tandem repeats of a single nucleotide (e.g. 
GGG) were avoided, where possible. 
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D.2 Primer Information 
Table D.2.1 shows relevant primer information, such as size, melting temperature 
(Tm), GC content, sequence and product size. The primer pair (promA) for the 
promotor region amplifies the section closest to the first exon. Likewise, the exon 4 
fragment (4a) includes the coding part of the exon, and not the entire exon. 
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Table D.2.1 Primer sequences utilised and relevant information 
Amplicon Primer pair Size (bP) Product size (bp) TMoC %GC Sequence 
promA CTLA4FPromA 21 55.5 52.3 5 J ggaccattagaaggatggtgc 3 J 
CTLA4RPromA 20 372 54.9 50 5 J ttacgagaaaggaagccgtg 3 J 
Exon 1 CTLA4F1 20 53.9 50 5 J gttgagtgcttgaggttgtc 3' 
CTLA4R1 20 443 55.5 50 5 J atcactgcctttgactgctg 3 J 
Exon2 CTLA4F2 19 52.7 52.6 5 J ggatgaagctagaaggcag 3 J 
CTLA4R2 20 578 53.0 50 5 J gctaccatgtggtacagaac 3' 
Exon3 CTLA4F3 20 55.4 55 5 I gcctggaagctctaatgtcc 3 J 
CTLA4R3 20 367 57.0 55 5' atgcctacggttctagtgcg 3' 
Exon 4a CTLA4F4a 21 56.3 52.3 5 I accagctagggacccaatatg 3 I 
CTLA4R4a 20 427 53.5 50 5' ctgaaagtggagctgatgtg 3' 
3 J UTR CTLA4F3UTR 21 52.9 47.6 5' ccggagttgtctttatcatcc 3 J 
CTLA4R3UTR 21 296 56.1 47.6 5' acctgtgttaaacagcatgcc 3' 
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AppendixE 
Polymerase Chain Reaction (PCR) 
E.1 Materials 
E.1.1 Equipment 
• Sterile 0.5 m1 and 1.5 m1 microcentrifuge tubes (Axygen Scientific, Union 
City, USA) 
• Gilson Pipetman (PlOOO, P200, P20 and P2) (Gilson Medical Electronics, 
Villiers-Ie-Bel, France) 
• Sterile filter pipette tips (Whitehead Scientific, Cape Town, South Africa) 
• RoboCycler Gradient 40 Thermal Cycler with hot lid (Stratagene, Los Angeles, 
USA) 
• Force 7 Microcentrifuge (Denver Instrument Company, Denver, USA) 
• Super-Mixer 220V Vortex (Lab-Line Instruments, Melrose Park, USA) 
E.1.2 Reagents 
• Deoxynucleotide Triphosphates (dNTPs) (Promega, Madison, USA) 
• Primers (forward and reverse) (See Appendix D) 
• MgC}z 25mM (Promega, Madison, USA) 
• Mg-free PCR Buffer (Promega, Madison, USA) 




• Work on ice. 
• Use gloves at all times to prevent contamination. 
• In a sterile 1.5 ml microcentrifuge tube, make up the following PCR cocktail: 
Table E.2.1 PCR reagent cocktail per PCR reaction 
Reagent [Stock] Volume (JIl) [Final] 
Primers each (forward 25 IlM or 10 IlM 0.2 to 0.5 IlM 
and reverse) (refer to table E.2.2.) 
MgCh 25mM 5 2.5mM 
Buffer lOX 5 IX 
DNTPs (Each) 2.5 mM 50llM 
Taq DNA polymerase 5 U/IlI 0.2 1 Unit 
dH20 34.8 
• Aliquot the cocktail into 0.5 ml microcentrifuge tubes (48 III per tube). 
• Add 2111 (l00 to 200 ng) genomic DNA to each reaction (Add 2 III dH20 in 
stead of DNA to one of the tubes to serve as a negative control). 
• Vortex tubes and centrifuge briefly. 
• Perform the following PCR reactions in the thermocycler, ensuring that the hot 
lid is switched on to prevent evaporation of samples: 
Denaturation at 95°C for 1 min. 
35 Cycles of denaturation at 95°C for 30 s, annealing at the specified 
temperatures (refer to table E.2.2) for 30 s and elongation at 72°C for 30 s. 
Final elongation step at 72°C for 7 min. 
• Store PCR products at 4°C until further use. 
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Table E.2.2 Stock primer concentration and Ta for the PCRs performed. 
PromA 1 2 3 4a 3'UTR 
Annealing 
53°C 53°C 59°C 55°C 55°C 55°C temperature 
[Primer] 
25 10 25 25 10 10 
( ... M) 
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AppendixF 
Polyacrylamide Gel Electrophoresis (pAGE) 
F.l Solutions 
F.1.1 Acrylamide-Bisacrylamide solution (ABA) 
Acrylamide(Pr~ Madison, UK) 300A, (60 g) 
Bisacrylamide (Promega, Madison, UK) 0.8% (1.6 g) 
Make up to 200 mJ with dlLO 
F.1.2 lOX TBE 
Tris (MW = 121.14) 540 g 
(Merck Chemicals, Wadeville, South Afiica) 
Boric Acid (Merck Chemicals, Wadeville, South Afiica) 275 g 
EDTA(Merck Chemicals, Wadeville, South Afiica) 37 g 
Make up to 5 L with dH20 and adjust pH to 8.3 
Autoclave to sterilize for 30 min 
F.1.3 100/'0 Ammonium Persulpbate (APS) 
APS (Promega, Madison, USA) 1 g 
Make up to 10 m1 with dH20 
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F.t.4 Bromophenol Blue Loading Dye 
Bromophenol Blue 0.25% w/v (0.25 g) 
(Associated Chemical Enterprises, Johannesburg, South Africa) 
Sucrose (Saarchem, Krugersdorp, South Africa) 400"{' wlv (40 g) 
0.5M EDTA (PH8) 4 mJ 
(Merck Chemicals, Wadeville, South Africa) 
Make up to 100 m1 with dH20 
F.t.S 6% Acrylamide Gel 
10XTBE (F. 1.2) 4 mI 
ABA (F. l. I) 8 mI 
Make up to 40 ml with dH20 
Add to this: 
APS (F.l.3) 400 JlI 
TEMED (Merck Chemicals, Wadeville, South Africa) 40 1.11 
Mix well 
F.t.6 Ethidium Bromide Staining Solution 
Ethidium bromide (500 ng/mJ) 200 JlI 
(Roche Diagnostics, Randburg, South Africa) 
dH20200ml 





• Hoefer Vertical Slab Gel Unit, SE600 series with gel aparatus (Hoefer, GE 
Heahhcare, Vienna, Austria) 
• Hoefer PS 1500 DC Power Supply (Hoefer, GE Healthcare, Vienna, Austria) 
• Hamilton Microliter Syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) 
• Gel Documentation system, UVItech (UVItech Limited, Cambridge, UK) 
• Mitsubishi P90E(B) Video copy processor (Mitsubishi Electric Corporation, 
Tokyo, Japan) 
F.2.1.2 Reagents 
• 6% Acrylarnide Gel (F. 1.5) 
• IX TBE running buffer {F. 1.2) 
• 500 nglml Ethidium bromide {F. 1.6) 
• Bromophenol blue loading dye {F. 1.4) 
• 100 bp molecular weight marker (Promega, Madison, USA) 
F.2.2 Methods 
• Assemble gel apparatus by placing two glass plates, separated by 1.5 mm 
spacers and kept together with clamps, vertically onto a gel stand, and secure 
using cams. 
• Make up a 6% Acrylamide solution (F.I.5) and pour between the glass plates 
in the gel setup. 
• Ensure all air bubbles are removed. 
• Insert a 20 weJIl.5 mm gel spacer comb and allow to set for at least 45 min. 
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• Carefully remove the comb from the gel. 
• Assemble the upper buffer chamber on top of the gel and clamp into place. 
• Pour 500 ml IX TBE Buffer into the upper buffer tank. 
• MIX 5 fll DNA with an equal amount ofPCR loading dye. 
• Using the Hamilton syringet carefuJJy load samples into the wells. 
• To one of the wells add 10 fll 100 bp DNA step ladder (diluted 1:2 with 
bromophenol blue loading dye) to serve as a size standard. 
• Run the samples in IX TBE running buffer at 270 V for I to 1.5 h. 
• Remove gel and stain in Ethidium Bromide solution for 10 min. 
• Visualise PCR fragments using the gel documentation system and take a 




G.l Restriction Enzyme Digests 
G.I.I Materials 
G.I.I.I Equipment 
• Techne Dri-Block DB' 2D Heating block (Techne, Cambridge, UK) 
• Force 7 Microcentrifuge (Denver Instrument Company, Denver, USA) 
• Super-Mixer 220V Vortex (Lab-Line Instruments Inc., Melrose Park, USA) 
• Gilson Pipetman (PlOOO, P2OD, P20 and P2) (Gilson Medical Electronics, 
Villiers-Ie-Bel, France) 
• Sterile pipette tips (Whitehead Scientific, Cape Town, South Africa) 
• 0.5 ml and 1.5 ml sterile microcentrifuge tubes (Laboratory Scientific, Cape 
Town, South Africa) 
G.I.I.2 Reagents 
• Enzymes (see table G. 1.2. 1) 
• Buffers (see table G.l.2.l) 
• BSA (supplied by enzyme manufacturers) 
G.I.2 Methods 
• Working on ice, make up a reaction mixture of the appropriate enzyme and 
corresponding buffer (see table G.1.2.l) in a 1.5 ml microfuge tube to a final 
volume of 10 III per reaction with dH20. For MnlI digestions, include 2 Ilg 
BSA according to the manufacturer's instructions. 
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Table G.t.l.t Individual reaction components for the 4 RE analyses. 
(E] BuO'er Digestion 
Polym Enzyme (U) Buffer lOX (pi) time (h) 
-318 CIT 
MnlI (New England 
I NEBuffer2 2 I 
BioLabs, Ipswich USA) 
+49A1G 
Ita! (Roche, Mannheim, 
I BufferH 2 3 
Germany) 
CT60G/A 
HpyCH4W (New England 
I NEBufferl 2 1.5 
BioLabs, Ipswich, USA) 
polym = polymorphism 
[E] = enzyme conoentration 
U = Units 
• Vortex well and spin down briefly in a microcentrifuge. 
• Aliqout 10 Jl1 of the above cocktai1 into 0.5 mI microcentrifuge tubes. 
• Add 5 to 10 JlI ofPCR product (depending on the intensity of the PCR bands) 
to the enzymes in the tubes. Make up the volume in each tube to 20 JlI with 
deionised water. 
• Include a positive control with each set of reactions to confirm complete 
digestion of product. 
• Vortex and spin down briefly in a microcentrifuge. 
• Incubate at 37°C as indicated in table G.I.2.1. 
• Analyse digestion products by electrophoresis on 60/0 PAGE (Appendix F). 
Inc1ude a predigestion PCR product. Stain with ethidium bromide and 
photograph the gel. 
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G.2 Restriction Maps 
G.2.1 CTLA4 PromA 
CTLA4 PromA Wild type 
372 base pairs 
Msel 
Trull 
ggaccattagaaggatggtgcttcacagatagaatacagtttttattaatgatgcctagacaaatcctgccatta base pairs 




gcccaagggctcagaaagttagcagcctagtagttttggagttgtcaatgaaatgaattggactggatggttaag base pairs 
cgggttcccgagtctttcaatcgtcggatcatcaaaacctcaacagttactttacttaacctgacctaccaattc 76 to 150 
Tru9l 
MnlI 
gatgcccagaagattgaataaaattgggatttaggaggacccttgtactccaggaaattctccaagtctccactt base pairs 
ctacgggtcttctaacttattttaaccctaaatcctcctgggaacatgaggtcctttaagaggttcagaggtgaa 151 to 225 
MnlI 
agttatccagatcctcaaagtgaacatgaagcttcagtttcaaattgaatacattttccatccatggattggctt base pairs 
















Table by Enzyme Name 
Positions 
of sites 












301 to 372 
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CTLA4 PromA -318 CIT 
372 base pairs 
Msel 
Trull 
ggaccattagaaggatggtgcttcacagatagaatacagtttttattaatgatgcctagacaaatcctgccatta base pairs 




gcccaagggctcagaaagttagcagcctagtagttttggagttgtcaatgaaatgaattggactggatggttaag base pairs 
cgggttcccgagtctttcaatcgtcggatcatcaaaacctcaacagttactttacttaacctgacctaccaattc 76 to 150 
Tru9l 
MnlI 
gatgcccagaagattgaataaaattgggatttaggaggacccttgtactccaggaaattctccaagtctccactt base pairs 
ctacgggtcttctaacttattttaaccctaaatcctcctgggaacatgaggtcctttaagaggttcagaggtgaa 151 to 225 
Msel 
Trull 
agttatccagatccttaaagtgaacatgaagcttcagtttcaaattgaatacattttccatccatggattggctt base pairs 





Table by Bnzyme Name 
Bnzyme No. Positions Recognition 
name cuts of sites sequence 
MnlI 2 188 325 cctc 
Msel 3 46 146 240 t/taa 
Trull 3 46 146 240 t/taa 
Tru9l 3 46 146 240 t/taa 
Every enzyme analyzed cuts this sequence. 
base pairs 
301 to 372 
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G.2.2 CTLA4 Exon 1 
CTLA4 Exon 1 Wild Type 
443 base pairs 
gttgagtgcttgaggttgtcttttcgacgtaacagctaaacccacggcttcctttctcgtaaaaccaaaacaaaa base pairs 
caactcacgaactccaacagaaaagctgcattgtcgatttgggtgccgaaggaaagagcattttggttttgtttt 1 to 75 
aggctttctattcaagtgccttctgtgtgtgcacatgtgtaatacatatctgggatcaaagctatctatataaag base pairs 
tccgaaagataagttcacggaagacacacacgtgtacacattatgtatagaccctagtttcgatagatatatttc 76 to 150 
tccttgattctgtgtgggttcaaacacatttcaaagcttcaggatcctgaaaggttttgctctacttcctgaaga base pairs 
aggaactaagacacacccaagtttgtgtaaagtttcgaagtcctaggactttccaaaacgagatgaaggacttct 151 to 225 
ItaI 
cctgaacaccgctcccataaagccatggcttgccttggatttcagcggcacaaggctcagctgaacctggctacc base pairs 
ggacttgtggcgagggtatttcggtaccgaacggaacctaaagtcgccgtgttccgagtcgacttggaccgatgg 226 to 300 
aggacctggccctgcactctcctgttttttcttctcttcatccctgtcttctgcaaaggtgagtgagacttttgg base pairs 
















Every enzyme analyzed cuts this sequence. 
base pairs 
376 to 443 
113 
CTLA4 Exon 1 +49 AlG 
443 base pairs 
gttgagtgcttgaggttgtcttttcgacgtaacagctaaacccacggcttcctttctcgtaaaaccaaaacaaaa base pairs 
caactcacgaactccaacagaaaagctgcattgtcgatttgggtgccgaaggaaagagcattttggttttgtttt 1 to 75 
aggctttctattcaagtgccttctgtgtgtgcacatgtgtaatacatatctgggatcaaagctatctatataaag base pairs 
tccgaaagataagttcacggaagacacacacgtgtacacattatgtatagaccctagtttcgatagatatatttc 76 to 150 
tccttgattctgtgtgggttcaaacacatttcaaagcttcaggatcctgaaaggttttgctctacttcctgaaga base pairs 
aggaactaagacacacccaagtttgtgtaaagtttcgaagtcctaggactttccaaaacgagatgaaggacttct 151 to 225 
ItaI ItaI 
cctgaacaccgctcccataaagccatggcttgccttggatttcagcggcacaaggctcagctgaacctggctgcc base pairs 
ggacttgtggcgagggtatttcggtaccgaacggaacctaaagtcgccgtgttccgagtcgacttggaccgacgg 226 to 300 
aggacctggccctgcactctcctgttttttcttctcttcatccctgtcttctgcaaaggtgagtgagacttttgg base pairs 
















Every enzyme analyzed cuts this sequence. 
base pairs 
376 to 443 
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G.2.3 CTLA4 3' UTR 
CTLA4 3'UTR Wild Type 
296 base pairs 
ccggagttgtctttatcatccttgcatttgaatattgtgttcaaatttttgattgattcattcagtatctggtgg base pairs 
ggcctcaacagaaatagtaggaacgtaaacttataacacaagtttaaaaactaactaagtaagtcatagaccacc 1 to 75 
agtctccaatattagaaatactggaaacaaactgaaaaaccacaaaaggacaaataatgcttcatgagtcagctt base pairs 
tcagaggttataatctttatgacctttgtttgactttttggtgttttcctgtttattacgaagtactcagtcgaa 76 to 150 
tgcaccagccattacctgcaagtcattcttggaaggtatccatcctctttccttttgatttcttcaccactattt base pairs 





















CTLA4 3'UTR CT60 G/A 
296 base pairs 
ccggagttgtctttatcatccttgcatttgaatattgtgtttaaatttttgattgattcattcagtatctggtgg base pairs 
ggcctcaacagaaatagtaggaacgtaaacttataacacaaatttaaaaactaactaagtaagtcatagaccacc 1 to 75 
agtctccaatattagaaatactggaaacaaactgaaaaaccacaaaaggacaaataatgcttcatgagtcagctt base pairs 
tcagaggttataatctttatgacctttgtttgactttttggtgttttcctgtttattacgaagtactcagtcgaa 76 to 150 
tgcaccagccattacctgcaagtcattcttggaaggtatccatcctctttccttttgatttcttcaccactattt base pairs 
acgtggtcggtaatggacgttcagtaagaaccttccataggtaggagaaaggaaaactaaagaagtggtgataaa 151 to 225 
gggatataacatgggttaacacagacatagcagtcctttataaatcaattggcatgctgtttaacacaggt 
ccctatattgtacccaattgtgtctgtatcgtcaggaaatatttagttaaccgtacgacaaattgtgtcca 
The following endonucleases were selected but don't cut this sequence: 
MaeII / HpyCH4 IV 
base pairs 








• Sterile 0.2 m1 microcentrifuge tubes (Southern Cross Biotechnology, Cape 
Town, South Africa) 
• Gilson Pipetman P20 (Gilson Medical Electronics, Vtlliers-Ie-Bel, France) 
• SteriJe pipette tips (Whitehead Scientific, Cape Town, South AJiica) 
• Force 7 Microcentrifuge (Denver Instrument Company, Denver, USA) 
• Hybaid OmniGene Thermal Cycler (Hybaid, Teddington, MiddJesex, UK) 
• W AVE Nucleic Acid Fragment Analysis System (Transgenomic, Omaha, 
USA) 
• WA VEMAKERnt software (Transgenomic, Omaha, USA) 
• Super-Mixer 220V vortex ~Line Instruments, Melrose, Park, USA) 
H.I.I.2 ~ts 
• WAVE High- and Low-Range Mutation Control Standards (Transgenomic, 
Omaha, USA) 
• DHPLC EJution Buffer 
• TEAA (Transgenomic, Omaha, USA) 
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• 25% Acetonitrile (Honeywell Burdick and Jackson, Morristown, USA) 
in water (Transgenomic, Omaha, USA) 
H.1.1.3 PCR products 
• Wild type DNA PCR products 
• PCR products to be screened 
RI.2 Methods 
• To determine the screening temperatures, enter the sequence of the DNA 
fragment to be screened into the WA VEMAKER 1M Software (Transgenomic 
Inc., USA) and calculate the percentage helical fraction versus the melting 
temperature for the fragment. Thereafter, calculate the temperatures at which 
the entire fragment will be eluted from the column. More than one temperature 
may be needed for large fragments. 
• To the PCR product from each affected individual to be tested add an equal 
volume of wild type PCR product of approximate same intesity (Allow 5 JlI per 
screening temperature). 
• Denature for 5 min at 95°C on the thermal cycler and allowed to cool slowly to 
room tempeiature on the block for at least 45 min for renaturing to take place. 
• Place heteroduplex mixes in the WA VB autosampler and enter the appropriate 
methods into the sample spreadsheets provided by the WA VEMAKER 1M 
Software (Transgenomic Inc., USA), according to the manufacturer's 
instructions. 
• Screen the samples at the predetermined temperature for each exon (see table 
H.I.2.1.) alongside the WA VB High- and Low-Range Mutation Control 
Standards (Transgenomic Inc., USA). 
• Analyse data with the WA VEMAKER TM Software by comparing the 
chromatograms of sample DNA to that of the negative control. 
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Table H.1.2.1 Temperatures at which fragments for each 60B were eluted during 
DHPLC screening. 
Temperatures screened (OC) 
AmpliCOB 1 2 3 4 
Promotor 57 
1 60.0 61.5 
2 55.9 57.3 60.4 62.5 
3 57.6 59.0 
4a 65.0 




• Hoefer Vertical Slab Gel Unit, SE600 series with gel aparatus (Hoefer, GE 
Heahhcare, Vienna, Austria) 
• PS 1500 DC Power Supply (Hoefer, GE Healthcare, Vienna, Austria) 
• Hamilton Microliter Syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) 
• Gel Documentation system, UVItech (UVItech Limited, Cambridge, England) 
• Mitsubishi P90E(B) Video copy processor (Mitsubishi, Tokyo, Japan) 
• Magnetic Stirrer (LASEC, Cape Town, South Africa) 
• 5 and 10 ml Sterilin Sterile Disposable Plastic Pipettes (Bibby Sterilin, 
Staffordshire, UK) 
• Yihder TS-500 Orbital Shaker (LASEC, Cape Town, South Africa) 
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H.2.1.2 Reagents 
• SSCP loading buffer 
Fonnamide (VWR International, Poole, UK) 95% 
NaOH (Merck Chemicals, Wadeville, South Africa) IO mM 
EDTA pH 8 (0.5M) (Merck Chemicals, Wadeville, South Africa) 20 mM 
Bromophenol Blue 0.02% 
(Associated Chemical Enterprises, Johannesburg, South Africa) 
Xylene Cyanol (Sigma-Aldrich, Steinbeim, Germany) 0.02% 
• Non denaturing MDE-SSCP gel mixture 
2X MDE gel solution (Cambrex Bio Science, Rockland, USA) 15 ml 
lOX TBE (Appendix F.I.2) 1.8 ml 
Glycerol 3 ml 
(Merck Chemicals, Wadeville, South Africa) 
If glycerol was not added, the 3 ml were substituted with dH20 
Make up to 30 ml with dH20 
• Silver staining solution I 
0.5 g AgNOJ (Merck Chemicals, Wadeville, South Africa) 
Make up to 500 ml with dH20 
• Silver staining solution n 
7.5 g NaOH (Merck Chemicals, Wadeville, South Africa) 
5 mJ 15% Fonnaldehyde (BDH Chemicals, Poole, UK) 
Make up to 500 ml with dH20 
• 10010 APS (Appendix F.1.3) 




• Assemble gel apparatus by placing two clamped glass plates, separated by 1.5 
mm spacers, vertically onto a gel stand, and secure using cams. 
• Pipette 5 m1 of the MDE gel mixture into a small glass beaker. Add 20 III 
lOOIoAPS and 20 III TEMED while stirring on a magnetic stirrer. 
• Immediately pour the mixture between the glass plates of the gel aparatus and 
allow to set. This forms a gel plug. 
• To the remaining MDE-SSCP gel mixture, add 175 J1l1001o APS and 17.5 III 
TEMED. 
• Pour this on top of the gel plug between the glass plates. 
• Ensure all air bubbles are removed. 
• Insert a 20 well 1.5 mm gel comb at the top of the gel and allow to set for at 
least 45 min. 
• Carefully remove the comb from the gel. 
• Place the upper butTer tank on top of the gel and clamp into place using cams. 
• Pour 500 ml 0.6X TBE Buffer into the upper buffer tank and fill the bottom 
tank with 2 L of 0.6X TBE. 
• Mix 5 III PCR sample with an equal amount ofSSCP loading buffer in 0.5 ml 
microcentrifuge tubes. 
• Vortex and spin down briefly in a microcentrifuge. 
• Denature samples at 95"C for 5 min on a heating block. 
• Place samples on ice for 5 min to prevent renaturation from taking place. 
• Using a Hamilton syringe, carefully load 1 0 pI of the samples into the wells. 
Add a positive control to one of the lanes, if available. 
• Include 10 III ofa 100 bp DNA step ladder (diluted 1:2 with bromophenol blue 
loading dye) on the gel to serve as a size standard. 
• Run the samples in the O.6X TBE rwming butTer at 350V for 18 h. 
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• Remove gel and rinse thoroughly in d.H20. 
• Place gel in 500 m1 silver staining solution I and shake gently for 10 min. 
• Rinse thoroughly with d.H20. 
• Place gel in 500 mI silver staining solution IT and shake gently untill bands are 
clearly visible. 
• Rinse thoroughly with dH20. 
• Visualise peR fragments using the gel documentation system with the use of a 
UV Iwhite light converter screen and photograph for future reference. 
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• Provided with kit (GFX PCR DNA and Gel Band Purification Kit, Amersham 
Biosciences, Buckinghamshire, UK): 
- GFX MicroSpin TM columns 
- Collection tubes 
• Gilson Pipetman PlOOO, P200 and P20 pipettes (Gilson Medical Electronics, 
Villiers-Ie-Bel, France) 
• Sterile pippette tips (Whitehead Scientific, Cape Town, South Africa) 
• Force 14 Microcentrifuge (Denver Instrument Company, Denver, USA) 
1.1.2 Reagents 
• GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences, 
Buckinghamshire, UK) 
• Provided with kit: 
- Capture buffer 
- Wash buffer 
• SABAX H20 (Adcock Ingram, Bryanston, South Africa) 
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1.2 Methods 
• Place one GFX column in a collection tube for each purification to be 
performed. 
• Add 500 ~l of capture buffer to the GFX column. 
• Transfer the DNA solution (up to 100 ~l) to the GFX column. 
• Mix thoroughly by pipetting the sample up and down 4-6 times. 
• Centrifuge in a microcentrifuge at 10,000 xG for 30 s. 
• Discard the flow-through by emptying the collection tube. Place the GFX 
column back inside the collection tube. 
• Add 500 ~l of wash buffer to the column. Centrifuge at full speed for 30 s. 
• Discard the collection tube and transfer the GFX column to a clean 1.5 ml 
microcentrifuge tube. 
• Apply about 30 ~l of SABAX H20 directly to the top of the glass fiber matrix 
in the GFX column. 
• To elute DNA in a more concentrated form reduce the elution volume to no 
less than 10 ~l. 
• Incubate the sample at room temperature for 1 min. 
• Centrifuge at full speed for 1 min to recover the purified DNA. 
• Note: 
Using low elution volumes to concentrate the DNA sample will reduce 
recovery. 
For 50 ~l elutions, the actual volume of sample recovered will range from 




Serum sCTLA4 Quantification by Enzyme-linked 
Immunosorbent Assay (ELISA) 
J.t Materials 
J.t.t EquiplDent 
• 5 and 10 ml Sterilin Sterile Disposable Plastic Pipettes (Bibby Sterilin, 
Staffordshire, UK) 
• Gilson Pipetman PlOOO and PIO (Gilson Medical Electronics, Villiers-Ie-Bel, 
France) 
• Repeater pipette (Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany) 
• Eppendorf 12.5 m1 CombitipS® (Eppendorf-Netheler-Hinz GmbH, Hamburg, 
Germany) 
• Beakers, flasks and cylinders for preparation of reagents 
• Wash bottle (Laboratory Scientific, Cape Town, South Africa) 
• Microwell strip reader (Anthos hill, Anthos Labtec Instruments, Salzburg, 
Austria) 
J.l.2 Reagents 
• Human sCTLA4 ELISA kit (Bender MedSystems GmbH, Vienna, Austria) 
• Reagents provided by the manufacturer: 
- Microwell plate coated with monoclonal antibody (murine) to human 
sCTLA4 
- Biotin conjugate anti-sCTLA4 monoclonal (murine) antibody 
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Standard, lyophilised, 20 nglml upon reconstitution 
20X Wash buffer concentrate (PBS with 1 % Tween 20) 
Assay buffer concentrate (PBS with 1 % Tween 20 and 10% BSA) 
Sample diluent (buffered protein matrix) 
Substrate solution I (tetramethyl-benzidine) 
Substrate solution II (0.02% buffered hydrogen peroxide) 
Stop solution (lM Phosphoric acid) 
Adhesive plate covers 
J.2 Methods 
• Allow reagents to come to room temperature and mix thoroughly without 
foaming before use. 
• Determine the number of microwell strips required to test the desired number 
of samples plus appropriate number of wells needed for running blanks and 
standards. Each sample, standard, blank and internal control sample* should 
be assayed in duplicate. Remove extra microwell strips coated with 
monoclonal antibody (murine) to human sCTLA-4 from holder and store, 
tightly sealed, in foil bag with the desiccant provided, at 4°C. 
• Wash the microwell strips twice with approximately 300111 wash buffer per 
well with thorough aspiration of microwell contents between washes. Take 
care not to scratch the surface of the microwells. After the last wash, empty 
wells and tap microwell strips on absorbent pad or paper towel to remove 
excess wash buffer. Use the microwell strips immediately after washing or 
place upside down on a wet absorbent paper for not longer than 15 min. Do 
not allow wells to dry. 
• Add 100 III of sample diluent in duplicate to all standard wells. Prepare 
standard dilutions by pipetting 100 III of reconstituted sCTLA-4 standard, in 
duplicate, into two adjacent wells. Mix the contents by repeated aspiration and 
ejection and transfer 100 III to the two wells directly underneath, respectively. 
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Take care not to scratch the inner surface of the microwells. Continue doubly 
diluting five times, creating two rows of sCTLA-4 standard dilutions ranging 
from 10 to 0.16 ng/mI. Discard 100 III ofthe contents from the last microwells 
used. 
• Add 100 III of sample diluent in duplicate to the blank wells. 
• Add 90 III of sample diluent to the sample wells. 
• Add 10 III of each sample, in duplicate, to the designated wells. 
• Prepare biotin conjugate as per manufacturer's protocol. 
• Add 50 III of diluted biotin conjugate to all wells, including the blank wells. 
• Cover with a plate cover and incubate at room teperature (18° to 25°C) for 2 h 
with shaking at 100 rpm. 
• Remove plate cover and empty wells. Wash microwell strips as above and 
proceed immediately to the next step. 
• Prepare streptavidin-HRP as per manufacturer's protocol. 
• Add 100 III of diluted streptavidin-HRP to all wells, including the blank wells. 
• Cover with a plate cover and incubate at room temperature (18° to 25°C) for 1 
h with shaking at 100 rpm. 
• Prepare TMB substrate solution a few min prior to use as per manufacturer's 
protocol. 
• Remove plate cover and empty wells. Wash microwell strips as above and 
proceed immediately to the next step. 
• Pipette 100 III of mixed TMB substrate solution to all wells, including the 
blank wells. 
• Incubate the micro well strips at room temperature (18° to 25°C) for 
approximately 10 min with shaking at 100 rpm. A void direct exposure to 
intense light. The colour development on the plate should be monitored and 
the substrate reaction stopped once an OD620 nm 0.6 - 0.65 is reached, before 
positive wells are no longer accurately recordable. 
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• Stop the enzyme reaction by quickly pipeuing 100 111 of stop solution into each 
well, including the blank: wells. It is improtant that the stop solution is spread 
quickly and uniformly throughout the microwells to completely inactivate the 
enzyme. 
• Read absorbance of each microwell immediately on a plate reader at 450 nm. 
Blank: the plate reader according to the manufacturer's instructions by using the 
blank: wells. Determine the absorbanc of both, the samples and the sCTLA-4 
standards. 
* An internal control sample was included in each run to account for inter-assay 
variation. 
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